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ABSTRACT 
£ 3 £ 68 3 3 6 St €! 6 :a 
Achieving representative, timely recruitment to acute stroke trials is challenging, yet 
little research has explored the factors determining whether or not stroke patients 
agree to participate in clinical research. This prospective study collected survey data 
from 200 acute stroke patients (or their consultees) from two NHS Trusts in the West 
Midlands to determine the influence of sociodemographic, clinical or attitudinal 
factors on decision-making about trial participation. Respondents were offered either 
a real or hypothetical trial. 
128 respondents (64%) agreed to trial participation. Few measurable factors were 
associated with decision-making, although patients able to consent for themselves 
were more likely to agree participation than consultees deciding on their behalf. 
Participation decisions may be strongly influenced by attitudes and perceptions about 
trial research rather than sociodemographic factors. Participants who perceived their 
stroke severity to be moderate or severe were significantly more likely to agree to trial 
participation. Respondents offered a real trial were almost six times more likely to 
participate than those offered a hypothetical trial. Disparities were found between 
self-rated stroke severity and clinician assessed NIHSS scoring. 
Acute stroke trial recruitment would benefit from recruitment strategy planning and 
training if trials are to produce timely findings based on representative patient 
samples. 
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CHAPTER 1 
INTRODUCTION 
 
Overview 
The focus of this thesis is to determine the willingness of stroke patients to participate 
in acute stroke research trials within the National Health Service (NHS) and to 
ascertain whether any identifiable patient or clinical characteristics influence the 
decision to participate. This chapter reviews the background to this study and 
research within the context of stroke medicine. A review of the pertinent literature is 
explored in chapter two and following this the research methodology is described. In 
the fourth and fifth chapters the results of this study are reported and discussed. A 
final chapter provides a conclusion to this study. 
 
In this introductory chapter, the first section provides an introduction to research 
within the NHS and recruitment to clinical trials. Section 1.2 details the challenges 
associated with recruitment to acute stroke trials in patients with acute stroke. This 
leads on to section 1.3 where an American study relevant to this project is discussed 
(Kasner et al 2009). Finally in section 1.4 the research objectives are outlined taking 
into consideration the gaps identified in the recruitment literature.  
 
1.1 Research in the NHS 
Research is important to patients, the Government and the Department of Health 
(DH) (NIHR CRN 2014a). The NHS constitution describes clinical research as ‘core 
business’ for the NHS and comes with a political duty and commitment. The Health 
and Social Care Act 2012 and recent government policies reinforce this commitment 
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to the promotion and delivery of health research as a core NHS role (DH 2010, DH 
2012a, DH 2012b, DH 2012c) since much of the care delivered within it is based on 
experience or uncertainties and lacks evidence but research provides this evidence. 
 
The National Institute for Health Research (NIHR) is the research arm of the NHS in 
England (NIHR CRN 2015). It was created to implement the government’s health 
research strategy: to embed research focused upon improving care and patient 
treatment into everyday clinical practice (DH 2006). The NIHR Clinical Research 
Network (CRN) and similar networks in Scotland, Wales and Northern Ireland provide 
the infrastructure to support the practical delivery of research in the NHS (DH 2011, 
UK Clinical Research Collaboration 2009).  
 
1.1.1 Clinical Trials 
Improvements in clinical care depend on implementation of an evidence base of 
research relating to the safety and effectiveness of treatments, devices and medical 
approaches. Clinical trials, and more specifically, Randomised Controlled Trials 
(RCTs) are considered the gold standard for research (Chalmers et al 1981; Stolberg 
et al 2004 and McDonald et al 2011) and attempt to address genuine uncertainty 
where clinical equipoise exists. 
 
RCTs are mostly quantitative, comparative, controlled experiments, with treatment 
effect less open to bias than observational studies (Stolberg et al 2004). The process 
of randomisation enables a fair comparison as the treatment a patient receives as 
part of a trial is randomly selected, based on chance (most commonly done by a 
computer programme but essentially, like tossing a coin) to decide treatment 
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allocation. Randomisation is considered to be a powerful experimental design since, if 
all other variables are equally accounted for (including unknown confounders), any 
difference in outcome can be attributed to the intervention (McGovern 2001). 
 
In order for the results of clinical trials to be generalisable and applicable to the wider 
population, a representative sample of patients needs to participate, reflecting the 
demographics and characteristics of the wider population on the basis of factors such 
as age, gender and ethnicity (Sheikh et al 2004). An under representation affects the 
generalisability of research findings (Hussain-Gambles et al 2004; Mason et al 2003) 
and may lead to inequalities in access to healthcare. Under recruitment to RCTs is 
problematic and well documented (Campbell et al 2007). 
 
Despite the importance of diversity of trial participants, Murthy et al (2004) noted (in 
the case of cancer research) that little information was available about factors that 
affect the representation of groups in clinical trials, namely race, ethnicity, age and 
sex.  
 
Involving participants from ethnic minority groups demands special consideration. For 
example, availability of Patient Information sheets (PIS) in a native language or 
presence of an interpreter, when necessary. Few trials have information leaflets 
translated to other languages, unless the trial is exclusively aimed at a particular 
ethnic group and trial sites may not have access to interpreters at the time of need. 
Furthermore, neurological deficits (including stroke), maybe more difficult to detect in 
ethnic minorities e.g. language impairment and slurred speech, if the patient is not 
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able to communicate in English, further hampering inclusion (Hussain-Gambles et al 
2004). 
 
Cultural barriers to randomisation may exist in a belief that illness is ‘God’s will’ and if 
it is God’s will, the patient will get better. Gaining an understanding of how patients 
decide whether or not to participate in a trial, and their attitudes towards research 
trials may enable the recruitment process to be more transparent, inform 
recommendations for improving the consenting process and lead to increased trial 
enrolment (Halpern, 2002).  
 
Wider ethical considerations regarding consent are extensively documented in the 
ethical literature. These include the more recent advances in law to address the 
difficulty of consent in emergency research and the alternatives to patient consent 
utilising a personal legal representative or a professional legal representative 
(statutory instrument, became UK law in 2004). Whilst this recognises the need for 
emergency research, for urgency of starting treatment, it does not support a waiver of 
consent for urgency of starting research, for example blood sample biomarker studies 
(low risk studies) requiring samples immediately on admission. These low risk studies 
are time sensitive in the Emergency Department (ED) with difficulty in delivery without 
a waiver of consent and yet the legislation does not currently reflect the urgency of 
starting research (Lemaire 2014).  
 
1.2 Stroke disease 
Whilst acute stroke trials have the potential to improve the evidence base for stroke 
care, the success and wider utility of stroke trials are often hampered by poor trial 
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recruitment. Overall, the numbers of stroke patients enrolled into trials are small and 
relatively little research relates to the actual recruitment of patients into acute clinical 
trials (Kasner et al 2009). 
 
Recruiting to clinical trials has its own challenges and recruitment is complicated yet 
further by an added time pressure in patients with an acute neurological event such 
as stroke, where therapies, such as thrombolysis, need to be administered rapidly for 
maximum effect (Rose and Kasner 2011).  
 
1.2.1 Definition of stroke 
The current definition of stroke supported by World Health Organisation dates back to 
1976 as a descriptive term for rapidly developing clinical symptoms lasting more than 
24 hours and comprising of a focal loss of cerebral function with a presumed vascular 
origin (Hatano 1976). Where symptoms last for less than 24 hours, a diagnosis of 
Transient Ischaemic Attack (TIA), a warning sign, may be applied.  Classically there 
are no warning signs of a stroke and the majority of strokes are not preceded by a 
TIA (Hankey 1996).  
 
The pathological background for stroke may either be ischaemic or haemorrhagic and 
is the interruption of the blood supply to the brain, affecting the supply of oxygen and 
nutrients and thus causing damage to the brain (Stroke association 2015). Ischaemic 
stroke (infarction) is the more common type of stroke (85%) and is the blockage of a 
blood vessel resulting from an array of risk factors (Feigin et al 2014). Haemorrhagic 
stroke is where a blood vessel bursts (accounting for approximately 15% of all 
strokes) and is often the result of high blood pressure (hypertension).  
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Subarachanoid haemorrhage (SAH) occurs mainly as a result of rupture of an 
aneurysm at the inferior surface of the brain. Although patients with SAH may develop 
symptoms in accordance with the current definition of stroke, it may not cause direct 
damage to the brain. Therefore they are often excluded from the majority of stroke 
studies (Truelsen et al 2000).  
 
Attempts at a 21st century definition of stroke with advances in science and 
technology have not gained full backing from the World and European stroke 
organisations primarily due to the inclusion of silent cerebral infarction and silent 
cerebral haemorrhage within a universal stroke definition (Sacco et al 2013). A new 
definition incorporating tissue criteria as well as clinical criteria can have significant 
effects on disease surveillance and prognosis (Sormani 2009). This would be critical 
for clinical research that reports outcome measures according to the accepted 
definition of stroke.  
 
1.2.2 Epidemiology 
There are approximately 152,000 strokes annually in the United Kingdom (UK) 
(Townsend et al 2012) with significant financial impact on the NHS, annual direct care 
costs in excess of £2.8billion and additional costs of lost productivity, disability and 
informal care costs estimated to raise this to £9billion a year (Saka et al 2009). Stroke 
continues to be the main cause of complex, adult disability worldwide and is the 
second most common cause of death globally (Lopez et al 2006). Fifty per cent of all 
stroke survivors are left with a disability (Adamson 2004; RCP 2014b).  
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With manifestations of coexisting conditions (such as ischaemic heart disease, 
peripheral vascular disease, diabetes and hyperlipidaemia for example) and of 
atherosclerotic disease, age remains the single most important risk factor for stroke 
(Seshadri et al 2006). In younger patients, stroke may be due to more unusual 
causes i.e. arterial dissection, migraine or blood disorders affecting people, of working 
age. 
 
South Asian, black African and black Caribbean people in the UK are at an increased 
risk of stroke compared to the rest of the UK population, with more exposure to risk 
factors notably diabetes, smoking and high blood pressure (Wang et al 2013). Black 
and south Asian people have strokes at a younger age compared to their white 
counterparts and black people are twice as likely to have a stroke compared to white 
people.  
 
1.2.3 Manifestation 
The symptoms of stroke are varied, often reducing patients’ physical and/or mental 
capabilities. Patients may present with any number or combination of symptoms. 
Physical impairments caused by stroke include those highlighted in the Act FAST 
campaign (Facial weakness, Arm weakness, Speech problems, and Time to get help 
if one or more of these signs are seen, DH 2013b), as well as individual or a 
combination of other symptoms such as co-ordination problems (ataxia), eye 
problems (hemianopia), decreased level of consciousness and cognitive impairments 
- which can present as: disorientation, poor memory and an inability to sequence a 
task. Each of these symptoms in isolation can complicate the consent process but in 
combination can prove a significant challenge to researchers. 
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Acute stroke may alter a patient’s level of consciousness, cause inattention / neglect 
and an inability to follow commands (RCP 2013). A deficit in this area may affect a 
patient’s ability to give valid consent for research (Demarquay et al 2005). However 
transient the current mental state may be, a consultee (usually a family member or a 
legal representative) may need to be approached to determine what the proposed 
participant’s wishes would be in relation to being involved in research.  
 
Speech problems such as expressive (expressed) or receptive (received) speech or 
aphasia (no speech) can result from a stroke. Verbal cues, guessing and suggestion 
are commonplace in the context of such deficits, especially in the early phases of 
stroke recovery. Patients can also suffer from excessive fatigue due to stroke 
(wakeful moments may be brief). This creates a challenge to determine if information 
about a research study has been understood and retained. Other forms of 
communication such as writing may equally be affected.  
 
Hemiplegia (weakness affecting one side of the body) is a commonly experienced 
symptom of stroke (Lawrence et al 2001). This may result in a dominant arm and 
hand being affected, so that the patient cannot hold a pen to sign his or her name on 
a consent form. Cerebellar strokes can present with a lack of co-ordination and result 
in difficulty writing. Some patients may be able to make a mark or use a non-dominant 
hand to indicate their agreement; in this case it would be considered best practice for 
this to be witnessed by a member of the clinical team. Another option may include 
witnessed verbal consent where clinical staff are present throughout the whole 
information giving and consent process to verify its conduct, protocol allowing. 
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The consent process is complex in stroke as, unlike many other conditions, 
understanding, retaining information, reading and writing may all be affected. 
Communication problems cannot in themselves be taken to indicate reduced mental 
capacity or inability to provide valid consent, however, they may raise concerns. 
Researchers use strategies such as pacing information, checking understanding and 
testing recall to highlight any issues within the support of the Mental Capacity Act 
(2005), DH (2005). Should mental capacity be affected by the stroke, a personal or 
professional legal representative can be consulted for research should they be 
available and the research protocol permits this. A personal representative or 
consultee often is a close family member. 
 
Consultee decision-making must always be based on the presumed will of the patient. 
In a limited review, Flaherty et al (2008) found only 30% of patients who experienced 
stroke provided their own consent whilst Kasner et al (2009) found 47%. In acute 
stroke studies, it is often necessary to involve family members in decision-making. 
This has been identified as a source of stress and a perceived burden of 
responsibility with urgent decision-making on behalf of a family member by 
consultees. Similar stress was not reported by self-consenting patients (Demarquay 
et al 2005).  
 
Supporting patients and their families at this stressful time is fundamental to ensuring 
patient choice and its availability for as long as possible. Lecouturier et al (2010) 
suggested that improvements in study participation could be achieved through 
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increasing the time spent with patients and families talking about research, but 
acknowledge that this may not always be possible in emergency research.  
 
In some emergency research scenarios, it is possible to go for deferred consent with 
a legal representative and verbal consent at the outset. Participants can then 
effectively ‘consent to continue’ post-recovery in a study where initial consent by the 
individual was not possible. Increasingly, studies have included documentation to 
enable this for example Roffe et al (2014), approved by National Research Ethics 
Service (NRES 2011b). This reflects one of the cornerstones of informed consent in 
that it is an on-going process (Berg et al 2001). 
 
1.2.4 Diagnosis 
Stroke remains a clinical diagnosis, and needs to be distinguished from stroke-mimics 
such as hemiplegic migraine, global amnesia or seizures (Rose and Kasner 2011). 
This is often in the context of acute neurological deficits, with an incomplete medical 
history, limited physical examination and imperfect neuroimaging. Previously fit 
people can suddenly become vulnerable patients unable to convey their wishes, 
communicate with medical staff and family or comprehend the seriousness of their 
situation.  
 
Initial nursing assessments undertaken as part of standard clinical care using tools 
such as the Glasgow Coma Scale (GCS), Face Arm Speech Time (FAST) Test, 
Recognition Of Stroke In the Emergency Room (ROSIER) and the National Institute 
of Health Stroke Scale (NIHSS) are often used to assess stroke patients (DH 2013b; 
Nor et al 2005; Brott et al 1989). They also serve as useful indicators of challenges 
 11 
that researchers may encounter when screening a patient for trial eligibility, 
discussing participation and obtaining informed consent.  
 
1.2.5 Management 
Computerised Tomography (CT) scanning, although more readily available and quick 
to perform in the emergency department, may not be sensitive enough to pick up 
early, subtle changes in brain matter, making radiological diagnosis difficult at an 
early stage (Yew and Cheng 2009). Recruitment to trials may be time sensitive and 
therefore it is not always possible to wait for neuroimaging confirmation of a stroke 
prior to recruitment.  As a result, some patients may no longer be eligible for a trial 
following confirmation of diagnosis (several days later in some cases).  
 
The acute phase of a stroke is generally considered to last 24-72 hours post stroke 
(Summers et al 2009). During this time a research approach can be unexpected and 
few people would have thought about the concept of research when feeling ‘well’ and 
now must consider it whilst ‘unwell’ and experiencing acute neurological symptoms.  
 
The acute phase of an illness is a difficult time within which to carry out research 
since symptoms can fluctuate, a diagnosis may not be fully apparent, the range of 
symptoms that can be experienced are extensive and their range of intensity can 
fluctuate. The priority of the patient and relatives is often not research as they attempt 
to rationalise what has occurred and are concentrating on “best treatment” following 
such a sudden event. This adds further difficulty to the recruitment process.  
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Clinical research undertaken in the early acute phase of a stroke is dependent upon 
effective collaboration between researchers and clinical nursing staff to safely 
implement protocols, given the inherent challenges of research in this context 
(Campbell et al 2015). 
 
Catastrophic changes are common in the brains of people with stroke and therapies 
need to be administered rapidly for maximum effect whether part of standard care or 
a research intervention (Rose and Kasner 2011). As a result, acute stroke studies 
often have a limited recruitment window within which participants can be included in 
the study, ranging from a few hours to 48 hours from stroke onset (UKCRN 2015). 
 
During this period, patients and their relatives may be seeking general stroke 
information and trying to understand the emergency situation they have found 
themselves in, and are not ready to consider research study-specific information. The 
acute neurological deficits resulting from a stroke can be transient, fluctuate and 
make recruitment to studies (specifically receiving consent) particularly challenging 
(Dani et al 2008).   
 
The opportunity for recruitment may be affected if the patient has delayed seeking 
medical attention for example, choosing to stay at home in the hope symptoms would 
resolve or being unable to call for help (Shah et al 2007), there is no clear onset time 
of symptoms, or if the patient is unable to convey this and presents alone. 
 
This is in contrast to some other disease areas where time may not a restricting factor 
for recruitment, mental capacity unaffected and a diagnosis may be well established, 
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for example in areas such as hypertension or diabetes. As a result, people can 
consent themselves, conditions maybe more chronic, long standing or allow for a later 
more relaxed introduction to research, not time pressured.   
 
Timely identification of potential research participants and anticipating and 
overcoming intrinsic impairments associated with stroke are therefore fundamental to 
successful recruitment to acute stroke studies. 
 
1.2.6 Research opportunities 
Information on ethnic minority participation rates across all disease specialities is 
documented in the literature (Mason et al 2003; Hussain-Gambles et al 2004). The 
importance of representation of individuals with different demographics has been a 
focus of many studies, as this will ensure that findings are generalisable to the wider 
society (Durant et al 2011). Under-representation of racial and ethnic minorities, 
gender and age have been reported extensively, in numerous specialities (Murthy et 
al 2004, Heiat et al 2002, Bartlett et al 2003).  
 
Historically, there were limited opportunities for patients to participate in stroke 
research, which was underfunded in comparison to other disease areas (such as 
cancer and heart disease) and had a limited public profile (Rothwell 2001).  The NIHR 
has raised the public profile of stroke research and provided new opportunities to 
offer research to patients who have experienced stroke. Between 2006 and 2014, 
stroke research benefited from a dedicated NIHR Stroke Research Network (SRN), 
which led to a six-fold increase in the number of patients who had experienced stroke 
participating in clinical research (NIHR CRN 2012a); and now forms part of a 
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cardiovascular research theme (of which six themes exist covering all disease 
specialties) across the whole of England. 
 
There are now more stroke studies than ever before included on the NIHR CRN 
Portfolio. Studies range from randomised clinical drug trials to observational studies 
and cover stroke prevention, diagnosis, acute treatment, rehabilitation and on-going 
care. While it may take several years to see the results of such research studies 
translated into clinical practice, the clear aim is to ensure that patients who have 
experienced stroke receive evidence-based care. 
 
Disparities in disease and medical setting mean that results from other disease areas 
are not necessarily applicable to a stroke population for a number of reasons: namely 
that stroke has a rapid onset and results in a loss of function (positive neurology) as 
opposed to causing pain. Some patients may not survive the initial event, whereas 
others may have reduced mental capacity and cognitive dysfunction that can affect 
their ability to provide valid informed consent.  
 
To participate in a research trial, potential patients must have the mental capacity to 
weigh up the benefits and risks of a clinical trial (NRES 2011b). A fundamental 
principle of UK law is the right of every adult to make their own decisions; unless 
there is proof that they lack the capacity to make a particular decision at the time it 
needs to be made. The Mental Capacity Act (MCA) 2005 (DH 2005) and the Adults 
with Incapacity (Scotland) Act 2000 provide guidance for determining a person’s 
capacity to make a decision. It specifies that it is important to help people take part as 
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much as possible in the decision process, and recognises that some participants may 
require help to make or communicate their decisions (vulnerable adults).   
 
To be valid, consent must be informed, competent and voluntary (ICH GCP 1996). 
Stroke, by virtue of the deficits that result from the condition and recent breakthroughs 
in treatment interventions (with time restrictions) adds complexity to this process 
(Liebeskind 2007). It is vital that cognitive impairments, visual disturbances, 
communication or physical deficits do not preclude patients from participating in acute 
stroke studies. Such deficits must be recognised and overcome to enable these 
patients to participate and ensure that research findings are applicable to the whole 
stroke population (McCormack and Reay 2013). 
 
In a Cochrane review by Treweek et al (2011), many studies are reported as having 
looked at recruitment to mock trials. A mock or hypothetical trial differs from a real 
trial in that no treatment results from giving consent but researchers must be mindful 
to ensure no confusion or deception occurs. Treweek et al conclude that it is difficult 
to know how findings from mock trials would apply to real trials. Other research has 
suggested that willingness to participate in a hypothetical trial to be a valid predictor 
of actual participation in a range of disease areas, such as infectious disease, arthritis 
and schizophrenia (Halpern et al 2001; Taylor et al 2007b; Jeste et al 2009) - 
although such a design cannot inform potential retention rates of participants.  
 
The use of hypothetical trials exposes the results to criticism that hypothetical choices 
may not reflect actual decisions for trial participation. However, as Durant et al (2011) 
point out, these approaches are widely used in survey research based on the theory 
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of ‘reasoned action’ that is, the behaviour is determined by someone’s intention to 
perform the behaviour (Ajzen and Fishbein, 1980).   
 
1.3 Previous Research 
Identifying and recognising factors associated with trial participation could aid 
research design, be cost and time saving and enable efficient targeting of additional 
support to groups. There is, however, little research on the actual recruitment process 
itself. One particular study in recent years, from a single, urban university hospital in 
Philadelphia, US has investigated participation in acute stroke trials (Kasner et al 
2009). Kasner et al (2009) used a survey tool to study who would take part in acute 
stroke research. The study consisted of a survey which included recruitment to a real 
trial (if patients met the criteria for trial entry) or a mock version (if the patients did not 
satisfy the inclusion criteria). Over a period of 15 months, 200 respondents completed 
the survey. Fifty-seven per cent stated they would participate in the proposed acute 
trial. Kasner et al found no differences in willingness to participate with respect to age, 
sex, race, educational level, ‘self-assessed’ stroke severity or stroke type, vascular 
risk factors or co-morbidities. Demographic factors, clinical factors and prior 
knowledge about research were found to have little impact on the decision to 
participate in acute stroke trials, but pre-existing negative attitudes and external 
influences about research strongly inhibited participation.  
 
Influences on the recruitment process have been highlighted by research and 
literature to date under the umbrellas of organisational factors, clinical disease factors 
and population specifics. Clinical and population factors pertinent to stroke have 
already been discussed. Organisational factors include researcher availability, 
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confidence of clinician, relevance of the research question and a scientific, rigorous 
design which fits with clinical practice (Fletcher et al 2007).  
 
Other potential organisational factors include delays due to legislative approval, the 
rate of active participation and commitment of recruiting sites, and the application of 
appropriate analysis and reporting procedures (McDonald et al 2011). However, it has 
been suggested that a feeling of hope is associated with research involvement (Weiss 
Roberts et al 2002) and video clips are used in healthtalkonline 
(www.healthtalkonline.org) promoting clinical trials from the participant perspective by 
those who have taken part in trials before. McDonald et al also propose that 
constraints on clinicians’ time and lack of available staff can largely be overcome with 
a team approach to research but still does not answer the question why some trials 
recruit well and others less well. 
 
The National Institute of Health Research (NIHR) identified that many trials up until 
2011 were not recruiting to target without extending their timescales. Recruitment was 
found to be most successful in centres that recruited their first patient within 30 days 
of approval. The NIHR has attempted to address this and incorporates it specifically 
in ‘time to target’ higher-level objectives (NIHR CRN 2014b). 
 
Elkins et al (2006), suggest that characterizing predictors of recruitment may help 
optimize future trial design. This has cost implications in terms of trial set-up, 
investment of working time for all parties involved in the research process and the 
need for timely research to keep pace with clinical advances, therefore relevance to 
the population.  
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The need for research to be embedded within standard care has been raised recently 
by Reynolds (2011) who found new technology and social media not to have 
increased participation. Reynolds highlighted that unhealthy people (possibly the 
more socioeconomically disadvantaged) and the elderly are less likely to be recruited 
and yet are more likely to need the benefits of new drugs developed as a result of 
clinical trial research. 
 
Kasner et al (2009) noted that in the context of an acute event, potentially influencing 
factors in decision-making were not clear. Gaining an understanding of how patients 
decide whether or not to participate in a trial, and their attitudes towards acute stroke 
research trials may enable the recruitment process to be more transparent, inform 
recommendations for improving the consenting process and lead to increased trial 
entry (Halpern 2002). Characterising the predictors of recruitment may help to identify 
barriers to recruitment, aiding trials in making more realistic estimates of the rate of 
enrolment (Elkins et al 2006). 
 
1.4 Gaps in the literature 
Although a variety of data and information are recorded regarding stroke admissions, 
for research purposes, a prospective research study to identify possible factors 
associated with trial participation has not been done in the UK for stroke disease. 
Information regarding the acceptability of research, and willingness of stroke patients 
to participate during the acute phase of their illness is important and it is not clear 
whether cultural differences or systematic healthcare differences would mean that 
results from the US would apply to the UK.  Currently a knowledge gap exists in our 
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understanding of influences on the decision to participate in acute stroke trials in the 
UK. 
 
By utilising a similar approach to Kasner, embedding survey research alongside 
recruitment to a real trial or hypothetical example, decision-making in relation to 
participation and the rationale behind it could be explored, compared and contrasted 
with the available literature and aim to fill the current gaps from a UK perspective. 
 
1.4.1 Study objectives  
 To determine whether demographic factors, level of education, prior research 
experience and issues related to the stroke experience itself have any impact on 
the decision to participate in acute stroke trials. 
 To assess general attitudes towards clinical trials, external influences and 
opinions regarding the participation decision. 
 To explore differences in trial participation decision-making between patients 
and their representatives, in conjunction with the reasons stated for the 
participation decision.  
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CHAPTER 2 
LITERATURE REVIEW 
 
Overview 
This chapter provides a review of the literature on recruitment to clinical trials. The 
literature will be reflected on critically with regard to its influence on the design and 
conduct of this study and the associated gaps in the evidence base identified in 
relation to acute stroke trial recruitment.  
 
The first section highlights research literature and the drivers associated with 
recruitment to clinical trials. Sections 2.2 explores recruitment and includes theories 
of behaviour and decision-making regarding participation in a clinical trial. This is 
followed by section 2.3 that describes the components of a recruitment process and 
valid, informed consent. Section 2.4 considers clinical trial participants and non-
participants. The final section summarises the literature, noting the research 
methodologies used in previous studies and reflects on its implications for this study.  
 
2.1 Research literature 
Research is important to patients, the government and the DH. A consensus wide 
consumer poll of 3000 people (NIHR CRN 2014a), found that 95% felt it was 
important that the NHS carries out clinical research and 89% reported they would be 
willing to participate in a study if diagnosed with a medical condition or disease. The 
NIHR is the research arm of the NHS and is an opportunity to embed research within 
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front-line activity and deliver the best possible treatments for patients based on the 
evidence of what works. 
 
For any type of clinical research study, patients must first be identified and assessed 
to determine whether they are eligible to participate (ICH GCP 1996). They must be 
given information about the research and time to consider whether they wish to 
participate. They must provide their written consent before receiving care in 
accordance with the research protocol, with relevant data collected and monitoring 
throughout to ensure patients’ safety and wellbeing.  
 
Clinical trials are used to guide advances in care and inform statutory bodies such as 
the National Institute for Health and Care Excellence (NICE) to secure the most 
consistent, high quality, evidence based care for NHS patients (Nice guidelines 
2014). Arguably, these guidelines are only as good as the evidence on which they are 
based, for example licences for treatments maybe for age specific or restrictive use 
due to the age range used in the trials, on which the granted licence was based.  
 
A recent example is the restricted licence for a thrombolytic drug (Tissue plasminogen 
Activator –TpA) which was granted in 2003 for use within a 3 hour window of stroke 
onset and in those under 80 year olds until the completion of further research which 
included older patients in the sample (IST Collaborative Group 2012) and a longer 
time window. Considering that the average age of stroke patients is close to the 
original maximum licence for use, a significant proportion of the stroke population was 
not able to access this treatment for several years. 
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The research process can be lengthy but many randomised controlled trials (RCTs) 
either fail to recruit sufficient participants or need to extend trial periods in order to 
meet target recruitment (Sully et al 2013). Extending trial length is not only costly but 
also risks minimising impact as clinical care advances over time (the research 
question is no longer valid or becomes irrelevant). Subsequent delays to clinical 
advances result in the continuation of weak evidence based practice in the absence 
of more robust research findings, and can ultimately result in diverting research 
resources away from future studies (McDonald et al 2011).   
 
2.1.1 Representative Sample 
Recruiting a representative sample is important in clinical trials so that results can be 
generalised to the wider population. Murthy et al. (2004) found enrolment in cancer 
trials for all patient groups to be low. In cooperative group cancer trials (breast, 
colorectal, lung and prostate cancer clinical trials), racial and ethnic minorities, 
women and the elderly were less likely to enrol than white males, and younger 
patients. Under-representation of certain demographic groups has also been reported 
by Heiat et al (2002) in heart failure clinical trials and by Bartlett et al. (2003) in a 
cholesterol trial. Of the studies published on enrolment to trials, the majority use 
retrospective data. Kumar (2003) argues for the need for prospective studies to 
determine the extent of lower inclusion rates for some patient groups i.e. those 
identified for trials but not included for randomisation.  
 
Disease stigma, anxieties related to understanding the implications of participation, 
worries about trial medication, as well as cost and time concerns were found to be 
common amongst ethnic minority groups (Rooney et al 2011). MacNeill at el (2013) in 
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an asthma paediatric study, found Bangladeshi parents to have a greater respect for 
medical opinion, limited grasp of spoken or written English and yet, increased 
participation (at the expense of limited understanding).  
 
Suggested improvements in the general literature for minority group inclusion note the 
use of multilingual trial documentation, employment of personal approaches (MacNeill 
et al 2013) and addressing researcher reluctance to include participants from all 
cultural and linguistic spectrums. Sheikh et al (2009) and Carman et al (2014) point 
towards a mixed methods approach to inform strategies on minority group inclusion. 
 
Despite a high incidence of acute stroke in the UK and significant cost implications for 
the NHS, the evidence base for treatments across the stroke care pathway is weak 
(National Clinical Guidelines for Stroke, 2008). Dani et al (2008) suggest this may be 
due to an inability of people with stroke to take part in the decision and informed 
consent process due to impairment, particularly where recruitment takes place soon 
after the stroke event. 
 
2.2 Recruitment to Clinical Trials 
The process of decision-making with regard to an acute clinical trial usually follows a 
set approach with the clinical team determining the suitability of a patient to be 
approached and their eligibility for enrolment (ICH GCP 1996). Information about the 
trial, the risks and potential benefits, and the requirements that participants will have 
to fulfil if they participate, is provided both in a verbal and written form and ‘sufficient 
time’ as deemed necessary, should be given. This is considered by ethics boards 
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prior to approval for research in the NHS and in line with trial design allows for the 
maximum available time to consider a research trial (Hardicre 2013). 
 
Various techniques used by individuals to make decisions have been documented 
over time and include: rational decision-making - weighing up pros and cons 
(advocated by the likes of Plato and Benjamin Franklin); simple prioritisation; 
satisficing – examining alternatives only until an acceptable one is found; maximising 
- where all alternatives are examined in order to determine the best one; elimination, 
acquiescence and superstition amongst others. 
 
Planning is not always possible prior to decision-making and its absence can add 
difficulty to the process. Behrendt et al (2011) used a qualitative approach to clarify 
patients’ needs and understanding about informed consent. Whilst a clear informed 
consent consultation was requested by respondents, adequate advanced notice was 
also specified. In contrast, over-thinking or over-analysing a situation can adversely 
affect decision-making so greatly that an action or decision is never taken.  
 
2.2.1 Decision-making 
Decision-making is largely regarded as a reasoning or emotional process resulting in 
the selection of a course of action from several different possibilities. A decision-
making process results in a final outcome, which may or may not prompt an action 
and is based on the values and preferences of the decision-maker. It can be rational 
or irrational and based on explicit or implicit assumptions.  
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Human performance has been studied from popular perspectives such as the 
psychological, cognitive and normative.  From a psychological perspective a decision 
is considered in the context of a set of needs, preferences and values. A cognitive 
perspective reflects an on-going process embedded within the interaction with the 
environment whilst a normative perspective is largely concerned with the logic of 
decision-making. 
 
The strategy in decision making of weighing up pros and cons is a recognised taught 
technique for decision-making (Franklin’s rule), however, without time, cognitive 
resources and access to relevant information (required to enable this) as a process, 
arguably it may not best describe how most people make decisions. Nightingale 
(2008) states that people simply decide without thinking too much about the decision 
making process. 
 
Uncertainty is formally integrated in the likes of decision analysis and robust decision 
research (Jungermann 1983). Despite exposure to logical decision-making in a 
medical institution, the general public are in a foreign environment, affected by a 
sudden, unexpected, serious health event with the need to rationalise the 
complexities of a clinical research trial. Rational choice theory incorporates the 
ideology that people try to maximise benefits whilst minimising costs (Schacter et al 
2011) and may play a role in decision-making. 
 
McCann et al (2013) studied recruitment to clinical trials highlighting an increasing link 
between potential participants’ health states and health care situations interacting 
with other considerations. In particular they note the nature and significance of trial 
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entry decisions influenced by communication and relationship to recruiter; 
implications of trial interventions and processes; perception of the common good 
(helping others) and what non/participation might reflect about them as individuals.  
 
Recency, wishful thinking, cognitive inertia, peer pressure, anchoring (unduly 
influenced by initial information shaping the view of subsequent information), role 
fulfilment, illusion of control, are all amongst other debated biases in judgement and 
decision-making. 
 
2.2.2 Theories of behaviour 
Many models and theories of human behaviour exist within the social sciences, the 
majority of which focus on the drivers of individual health behaviours, and have their 
roots within the discipline of psychology, although there are also a number of 
behaviour theories which focus on the behaviour itself or the relationship between 
behaviour, individuals and the social and physical environments within which they 
occur.  
 
2.2.2.1 Theory of Planned Behaviour (TPB) and reasoned action 
The Theory of Planned Behaviour (TPB) is one of the most commonly cited and 
applied behavioural theories, adopting a cognitive approach to explaining individuals’ 
attitudes and beliefs (Ajzen 1985, 1991; Ajzen and Madden 1986).  TPB evolved from 
the theory of actioned reason (Fishbein and Ajzen 1975), which puts forward intention 
to act as the best predictor of behaviour. 
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Intention is proposed as an outcome from a combination of attitudes towards a 
behaviour, positive and negative evaluation of the behaviour, its expected outcomes 
and subjective norms (social pressures) from the perception of what others may think 
should be done and a person’s inclination to follow these. Similarly, self-efficacy and 
perceived behavioural control may be additional components that influence 
behaviour.  TPB has been widely used in health by the likes of Armitage and Conner 
(2001) and more recently by Taylor et al (2007a) and Munro et al (2007) with 
evidence suggesting a strong correlation between behaviour and both attitudes 
towards that behaviour and perceived behavioural control components (Figure 2.1). 
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Figure 2.1: Theory of Planned Behaviour Model (Munro et al 2007) 
 
 
2.2.2.2 Health Belief Model (HBM) 
An alternative popular theory of behaviour, the Health Belief Model (HBM) argues that 
behaviour is determined by a number of beliefs about threats to well-being, 
effectiveness and outcomes of actions and behaviours (Hochbaum 1958; Rosenstock 
1966; Becker, 1974; Sharma and Romas, 2012). This is possibly more relevant when 
attempting to understand decision-making with regard to clinical trial participation, as 
the theory was designed and developed in the healthcare context, with perceived 
threat being central to the model, covering personal cognitive factors and the addition 
of self-efficacy (Bandura 1997) – with the recognition that stimuli may trigger adoption 
of behaviour (Figure 2.2). 
 
Proponents of the theory argue that it is particularly appropriate when seeking to 
explain or predict patterns of behaviour, but it has also been criticised for the 
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exclusion of social, economic or unconscious (habitual) determinants that are 
generally considered at least as important as personal cognitive factors in affecting 
decision-making processes. The HBM, however, does not take account of institutional 
factors outside of an individual’s control which maybe an important consideration for 
hospitalised patients or their next-of-kin who may be involved in a decision-making 
process such as that related to deciding on participation in a clinical trial. 
 
Figure 2.2: The Health Belief Model (Rosenstock 1974) 
 
 
 
With regard to predictive behaviour - whilst the mantra that has gained recognition 
over several decades that ‘the best predictor of future behaviour is past behaviour’, is 
noted in psychology texts (Johnston 2003), this is possibly too simplistic and past 
behaviour may merely be a useful marker as to what may happen in the future. Much 
has been written about the contribution of habit and the influence of personality typing 
on health beliefs and behavioural decision-making. Nevertheless, participants who 
have taken part in research before have an increased awareness of research. Durant 
et al (2011) found that those involved in research previously were more likely to sign 
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up for further studies when invited, provided they had not previously had a negative 
experience of research participation. 
 
Additional influences on decision-making include social, cognitive and cultural 
considerations. For example, the desire for a particular outcome e.g. wellbeing with 
the assumption that medication will result in improvements, financial incentives, 
previous experience, level of education, nurture (cultural influences – trust or mistrust 
of authorities), altruism, laissez faire or religion. 
 
2.2.3 Hypothetical trial behaviour 
A hypothetical (or mock) research trial differs from a real trial in that no treatment 
results from giving consent. Care must be taken to ensure that no deception occurs 
and that patients being offered the hypothetical trial are fully aware that they are not 
being asked to consent to participate in a ‘real’ trial. Various articles in the research 
literature argue that the use of hypothetical (mock) trials is a valid predictor of actual 
participation in trials (Halpern et al 2001), and that using hypothetical trials as a 
means of understanding patient decision-making about trial participation is a valuable 
way to assess the barriers to, and motivators of participation in a way that can be 
directly transferred to ‘real’ trials. However, according to Treweek et al (2011), it can 
be difficult to assess how findings from hypothetical trials would apply to real trials. 
Nonetheless, researchers such as Halpern et al (2001); Taylor (2007b); Jeste et al 
(2009) and Tehranisa and Meurer (2014) all report positive findings in relation to a 
decision for trial participation using hypothetical trials, in the areas of arthritis, 
schizophrenia and stroke.  
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Jeste et al (2009) used a mock trial in schizophrenia patients to test a multi-media 
consent process, recognising the potential for impaired decision-making capacity in 
the population group being studied. This allowed for understanding, appreciation, 
reasoning and expression of choice in trial participation as opposed to printed, text 
based consent forms for informing.  
 
Most recently, Tehranisa and Meurer (2014) used an acute stroke mock trial for 
patients presenting to hospital emergency departments to test the extent to which 
those approached to participate understood trial design (response adaptive 
randomisation, RAR). The authors found the trial design to be well understood by 
participants, although in this case, participants were without symptoms of stroke or 
other critical illness. 
 
Durant et al (2011) note that approaches using mock trials were widely used in survey 
research based on the theory of “reasoned action”, that the behaviour is determined 
by someone’s intention to perform the behaviour (Ajzen and Fishbein, 1980). 
 
Goldstein et al (2010) found independent predictors of willingness to enrol in acute 
stroke trials to include Catholic religion, looking at consecutive emergency 
department (ED) attenders and their opinion on participation in a stroke trial. 
 
In acute stroke studies, it is often necessary to involve family members in decision-
making as patients are not necessarily able to consent for themselves (DH 2005). 
This has been identified as a source of stress and a perceived burden of 
responsibility (Demarquay et al 2005). Kasner et al (2009) found surrogate decision 
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makers to be less inclined to agree to the participation of a patient compared to the 
patient who had experienced stroke themselves.  
 
2.2.4 Consultees 
Consultees or proxy decision-makers are approached regarding consent (or rather 
assent) for clinical trial participation, as a legal representative in cases where patients 
are unable to consent for themselves (Hardicre 2013). In practice, this is usually a 
next-of-kin - the rationale behind this comes from the recognition that a consultee is 
able to inform from a position of knowing the patient best and thus being aware of 
what the patient’s wishes may have been in this situation, had the patient been able 
to consent for themselves.  
 
Mead et al (2013) noted that due to acute stroke, many people are not able to 
consent for themselves and describe proxy consent as standard. In order to facilitate 
information provision, easy access patient information booklets were devised – 
utilising short sentences, a simple grammar structure and large well-spaced text. 
There is currently on-going use of the easy access booklets to determine the 
numbers of aphasic patients enabled to independently consent as a direct result of 
having this available and supports the consent process in that participants should be 
encouraged to take part in the process as much as they are able (DH 2005).  
 
Demarquay et al (2005) studied 56 stroke patients enrolled in urgent therapeutic trials 
and found (using multiple logistic regression) increasing age and baseline 
neurological deficit (as assessed by the Scandinavian Stroke Scale SSS) to be 
independent predictors of inability to give consent. The majority of patients (n=43, 
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77%) were consented by relatives and a proportion of these declared feeling 
uncomfortable with the decision citing psychological stress induced by urgent 
decision making.  The authors of the study conclude that the responsibility of consent 
usually relies on relatives and questions a potential inaccuracy of decision concerning 
a patient’s wishes or a conflict of interest. 
 
More recently, Bryant et al (2013) found that over a third of stroke patients required 
surrogate consent with little being known about the level of agreement between 
patient and surrogate in the time sensitive decision-making process. The authors 
used four hypothetical acute stroke scenarios and found high surrogate-patient 
agreement for clinical scenarios of 87%-96% but a drop to 49%-74% with a research 
scenario suggesting the accuracy between surrogate-patient agreement on 
participation decreases with a research scenario, noting a difference in the type of 
decision made (clinical versus research).  
 
Sanoff et al (2013) recorded calls to enrolling physicians. The most commonly cited 
reasons for non-enrolment were: unclear stroke onset time; pre-existing condition 
confounding outcome; mental incapacity and no legal representative; rapidly 
improving symptoms and no interpreter. Eleven per cent of legally authorised 
representatives, refused participation. 
 
Kasner et al (2009) similarly found that patients were more likely to agree to a 
research study than a consultee was on their behalf adding weight to Bryant et al’s 
(2013) call for further characterisation of the surrogate decision making in acute 
stroke, to be useful. 
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2.3 Components of recruitment 
Significant costs are associated with trials failing to meet recruitment targets or 
extending recruitment at the expense of limited resources being invested in new trials. 
A significant amount of current literature suggests both organisational and clinical 
disease factors affecting recruitment to trials. Adeoye et al (2012) suggest that 
improved recruitment rates could be achieved by capturing potential participants who 
are ‘eligible but not approached’ and ‘treated but not enrolled’.  
 
Prior to enrolment in a clinical trial, several important recognised steps would have 
needed to have occurred. Events ranging from the need to document pre-hospital 
activity immediately post event through to seeking medical attention and having a 
clinical trial ‘open to recruitment and accessible’ with resources (researcher) to offer a 
recruitment opportunity. The decision regarding trial participation rests with the 
competent decision-maker at this point. 
 
2.3.1 Presentation and recognition 
Early treatment and secondary preventive measures can reduce the brain damage 
associated with a stroke and treatment of stroke is very time dependent. The 
multimedia campaign and associated medical personnel training (ambulance crews) 
with FAST Campaign has led to increased recognition of symptoms (Mellor et al 
2014). However, in a UK project set in the West Midlands, Mellor et al (2014) found 
that delays arose from patients’ lack of recognition (or denial) of the significance of 
their symptoms, contact with primary care as opposed to the emergency services and 
lack of recognition of the nature and severity of the event by initial healthcare 
providers.  
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Of 2042 presenting acute stroke patients from a multi-ethnic population in the US 
during an 8 year period (2005-2013), 101 patients presented one-week after acute 
stroke, 58% were beyond 4.5 hours (the required time for early intravenous 
thrombolysis treatment) with diabetic patients less likely to arrive within the prescribed 
time period. Patients who were men, with a history of atrial fibrillation or flutter and 
experiencing a transient ischaemic attack were significantly more likely to arrive within 
the prescribed time. Black, African-America and Hispanic patients were less likely to 
arrive on time (Matos-Diaz et al 2015).   
 
Elkins et al (2006) found trials with a recruitment window of >6 hours had double the 
recruitment rates of those that use a recruitment window of <6 hours, suggesting a 
significant impact of time pressure. 
 
Further international research by Williams et al (2009) in a retrospective audit of 331 
presentations found 63% of cases presenting  >12 hours after symptom onset and 
subsequent long in-hospital delays with only 52% being assessed by a physician 
within an hour of presentation with intravenous thrombolysis treatment not being 
routinely performed. 
 
With access to intravenous thrombolysis treatment becoming more widely available in 
recent years, clinical trials in front line drugs such as IST-3, DIAS-4, ECCASS3/4, 
immediate CT and rapid assessment time have contributed to shorten delays post 
presentation but wake-up strokes, unknown time of onset and seeking help pre-
hospital remain potential delays (Penaloza-Ramos et al (2014). 
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2.3.2 Site setup and resource 
Barriers and facilitators to out of hospital stroke research were noted by Ankolekar et 
al (2014) who used semi-structured interviews to identify 13 themes associated with 
recruitment. Positive factors were noted to be simple stroke diagnostic tools, proxy 
consent and straightforward trial processes. Recruitment was reported to be easier 
with each new randomisation whilst barriers were reported as the emergency setting, 
lack of institutional support, rarity of condition and difficulty in attending training.  
 
Ahluwalia et al (2014) noted a trend towards increased understanding and 
satisfaction with the informed consent process by patients where additional resources 
of a video link phone were used pre-hospital but warn of possible risk as a result of 
increasing time at the scene of the event to intervention (time) within secondary care. 
 
Perceived clinical equipoise must exist in the research team and sufficient resources 
available for trial delivery when eligible patients are likely to present. Balancing 
resource with financial return is a significant consideration for trusts and Research 
and development (R&D) departments in the current financial climate. 
  
During a trial, changes such as a relocation of services, advances in clinical care, or 
local changes in clinical arrangements can all affect recruitment figures. Advances in 
clinical care may mean the research question becomes no longer valid during the trial 
or needs to be adjusted to complete the trial and create the evidence base for a 
particular aspect of clinical care for example CLOTS collaborative (2008). 
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For a recruitment opportunity to occur, a clinical trial must have received a favourable 
ethical and local (Trust research and development) approval, be open to recruitment 
at the emergency care facility and have the necessary resources to be able to offer 
this opportunity. 
 
Charting 300 subjects recruited for acute stroke trials, Elkins et al (2006) found that 
study entry criteria and organisational factors influenced recruitment rates. It is 
therefore necessary to not only have a trial open but also one open that patients are 
eligible for. 
 
Trial-related barriers to participation include additional demands from a trial protocol 
on the patient such as time, discomfort, worry and travel; preference for a particular 
outcome may dissuade participants from trials involving a randomisation, especially if 
the alternative is a placebo; some patients may not wish to take medication, change 
their existing medication or have a fear of the unknown or adverse events (Kaur et al 
2012). A complex trial design may not be in keeping with standard care treatment 
visits, requiring additional scheduling. Age, level of education, social circumstances, 
language and cultural issues (distrust of existing systems) may also have an impact. 
A complex trial design which outlines a schedule not in keeping with standard care 
treatment visits may require multiple additional clinic or hospital visits which may be 
difficult for those who would need to take time off work to meet trial commitments.  
 
Clinicians may have personal concerns with reluctance to ‘over-burden’ a patient with 
research at a difficult time evidenced by less recruitment of severely ill patients. 
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Resources required on site to deliver a study include study team members with 
knowledge of the study, delegation of trial procedures and a signed delegation of 
duties log with personnel able to action the necessary requirements. These staff need 
to be available when a patient presents in order to be in the time window for 
recruitment. Consideration therefore needs to be given to working hours, shifts 
patterns and extended hours cover within a 24/7 healthcare service.  
 
With the advent of the national research networks in 2006, the NIHR provided an 
infrastructure for research, funding and supplying research nurses amongst other 
initiatives, boosting recruitment (Darbyshire et al 2011). 
 
Leira et al (2009) found an increased likelihood of consent to trial participation with an 
increased number of research contact points. Utilising pre-arrival communication 
between investigator and potential participants proved successful with an increased 
consent rate in acute stroke trials within a cohort of 100 patients (trialled in US in 
2007). 
 
Information overload is deemed to be when there is a substantial difference between 
the volume of information provided and the extent to which people can make use of it. 
This can occur due to a problem processing and tasking (a possible consequence of 
the clinical effects of a patient having suffered a stroke) and as a result, can influence 
decision-making (Kutty and Himanshu 2007). Factors affecting information overload 
may appear on a personal level with an individual’s educational level, past 
experiences, the characteristics of the information in terms of quality, quantity and 
frequency, tasks, process, design and Information technology. Hall et al (2007) 
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described an illusion of knowledge, suggesting that too much knowledge can interfere 
with an individual’s ability to make a rational decision. Raynor et al (2007) found 
evidence outside trials that patients had a preference for verbal information from 
clinicians complemented by written information. 
 
Patient information sheets have been criticised in the literature in regard to trial 
recruitment. Iwanowski et al (2008) surveyed 24 investigators on informed consent for 
research about coronary syndromes and stroke findings. Despite there being no legal 
obligation to do so, investigators sought parallel consent from patients’ relatives in the 
majority of cases - due to the patient information sheets being considered as fully 
read in only 15% of cases and 80% of investigators considering the amount of 
information being given too lengthy. Similarly Shilling et al (2011), found that both 
practitioners and parents in paediatric clinical trials expressed dissatisfaction with 
patient information leaflets; reporting them to be too long and complicated.  
 
More recently Kirby et al (2013) tested the feasibility of electronic information 
provision, for an interventional study noting the amount of information accessed. 
From 1160 potentially eligible participants only 25% supplied an email address. Of 
those responding on email (106), 59% (n=63) booked to attend a recruitment clinic 
despite accessing no electronic information. Kirby concludes that written information 
may not be read, reemphasizes the importance of the consent interview and suggests 
new ways of presenting information are needed. 
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2.3.2.1 Informed Consent 
Clinical trials research consent differs from clinical care consent since the latter is 
based (at least in theory) on a body of evidence for a prescribed, recognised 
treatment and considered to be in the best interests of the patient. The former is 
carried out to create that body of evidence and may not directly benefit the 
participants themselves. 
 
Valid informed consent is at the centre of ethical research practice and is essential to 
protect the rights and safety of patients taking part in research. Several definitions of 
informed consent can be found in the literature based on the International Conference 
on Harmonisation for Good Clinical Practice (ICH GCP 1996), which stipulates: 
 
“A process by which a subject voluntarily confirms his or her willingness to 
participate in a trial, after having been informed of all aspects of the trial that 
are relevant to the subject’s decision to participate and by means of a written, 
signed and dated informed consent form.” (ICH, GCP E6 1.28) 
 
Any new information that becomes available and which might influence a decision to 
carry on with trial participation, must be shared with any recruits. Continued 
understanding of participation must also be present which reflects the on-going nature 
of the consent process. 
 
In order to participate in a clinical trial, valid informed consent to take part must be 
freely given and received. Care is needed due to cognitive and physical effects from a 
stroke so that words and details are not missed when presented with written 
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information. Alternative formats of documented trial details may need to be sourced to 
ensure that consent remains fully informed. 
 
In emergency research, time is limited and should patients be unable to consent 
themselves (DH 2005), independent physician consent as well as legal 
representative, verbal consent or exception to consent maybe appropriate 
approaches given ethical approval. Legislation has incorporated EU directives with 
statutory instruments to allow concessions to be made in the consent process for 
research in the emergency setting. Flaherty et al (2008) found that only 30% of 
patients who experienced stroke provided their own consent. 
 
Supporting patients and their families at this stressful time is fundamental to ensuring 
patient choice is available for as long as possible. Lecouturier et al (2010) suggested 
that improvements in rates of study participation could be achieved through 
increasing the time spent with patients and families talking about research, but 
acknowledge that this may not always be possible in emergency research. It is 
possible for participants to consent using conventional processes to continue in 
research post recovery and many studies have processes to enable this.  
 
Alternatively, an exception to consent was researched in the emergency department 
using a hypothetical stroke trial by Kleindorfer et al (2011) with the majority of 
ischaemic stroke patients being agreeable to enrolment. 
 
Ali et al (2006) used focus groups of individuals having had personal experience of 
stroke and found a preference to personal contact with researchers (face to face), 
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request for waiver of consent and agreement to family assent on behalf of 
incompetent patients. Whilst Lecouterier et al 2008 found that 50% of professionals 
were reluctant to agree with research without consent, a paradoxically higher 
percentage would personally take part in such a study.  
 
Masuca et al (2012) found patients consented faster than legal representatives and 
since emerging treatments are time sensitive, called for further efforts to target this for 
stroke where significant numbers of patients are not able to fully consent for 
themselves. 
 
Flexible consent procedures have made it possible to recruit target numbers into 
some stroke trials notably International Stroke Trial 3 (IST-3) using written consent, 
witnessed consent, assent or waiver of consent (Kane et al 2006).  
 
Consent for research is enshrined in UK law and considered to be a planned activity. 
To enable emergency care research the concept of deferred consent or a ‘waiver of 
consent’ has emerged and maybe considered by the research ethics board and 
(under strict requirements) maybe a recognised practice in a study (NRES 2011a).  
 
In the US, independent ethics committees, following strict requirements may approve 
a consent process that does not include some or all elements of informed consent or 
waiver the process. However, Lecouturier et al (2010) found waiver of consent not 
well documented in the literature and less advanced as a concept in the UK 
compared to the US. 
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Alternative consent strategies e.g. telephone consent and two-physician consent 
(although available) are not routinely used in clinical practice in isolation (Gilani et al 
2013). Recruiting 159 patients undergoing endovascular treatment for acute stroke 
Gilani et al (2013) found that alternative consent strategies did not adversely affect 
procedural characteristics (no time delay) or patient outcomes and such consent 
strategies maybe more time efficient than in-person consenting.  
 
Beauchamp and Childress (2009) advocate three elements of consent. The first is the 
provision of adequate information with a full and comprehensive outline of the 
research so that patients know exactly what is involved. According to the International 
Conference on Harmonisation Good Clinical Practice (ICH GCP 1996), 20 distinct 
elements are recommended for inclusion in patient information sheets. It is generally 
accepted that patients need to be given ‘enough’ information to make a valid informed 
decision, however, regulatory guidance and legislation favours maximum disclosure 
with researchers required to give ‘full’ information whether or not patients wish to 
receive it. Research in the literature has focused on whether this is information 
overload (Ferguson 2002, Fortun et al 2008) with Rose and Kasner (2011) 
highlighting that stroke trial patient information sheets typically range from 8 to 16 
pages depending on the complexity of the trial. 
 
A distinction between study and routine care is not always understood by participants 
(Lynoe et al 2004), lending support to the debate on whether informed consent is truly 
informed.  
 
2.3.3 Clinical disease 
 44 
Clinical disease symptoms can add complexity to the recruitment process and this is 
particularly evident in stroke disease where a sudden neurological event can have 
any combination of wide ranging symptoms. The need for alternative consent 
strategies, with a potentially unclear diagnosis during an acute event, with associated 
risk, despite clinical equipoise, may be an uncomfortable situation for a treating 
physician who may not wish to ‘burden’ a family with a decision for research at a 
difficult time.  
 
The timing of a research approach may influence participation. Immediately post 
event, on seeking medical help, research options may be the only access to some 
treatments or may be appealing to patients. Alternatively, when patients and their 
family have a diagnosis and are accepting of the prognosis, research may be more 
favourable as an option. The time post hyperacute and pre-rehabilitation could be a 
difficult time within which to advocate research from a professional perspective since 
there maybe no clarity in diagnosis or little information on prognosis. Equally it may 
be a difficult time to be open to the concept of a research opportunity from a patient’s 
perspective. A strategy for enrolment is often identified at site and is disease specific 
in many cases. 
 
Physicians may act as gatekeepers and maybe unwilling to participate in facilitating 
research trials themselves due to a lack of time, lack of resources (support staff), 
conflicting clinician / scientist role, lack of trials experience, lack of recognition and 
possibly an uninteresting research question (Rahman et al 2011). If the clinical team 
deemed it to be unlikely that the patient will survive the stroke event, they are often 
not approached for research (which may have an entry criterion related to whether or 
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not the patient is expected to survive for a minimum fixed period or for follow up).  
 
There could be disagreement in terms of uncertainty or equipoise amongst 
professional colleagues with low referral numbers due to lack of physician 
engagement. Physician colleagues may agree to be part of the trial whilst disagreeing 
with some aspects of it.  
 
Financial incentives may encourage investigator participation as well as protected 
time to carry out research duties or a research question in line with a physician’s 
interests with clear potential to improve patient care and regular feedback (Rahman et 
al 2011.)  
 
Ethnic disparities in regard to stroke disease exist in not only stroke incidence but 
also recurrence and mortality - which are higher particularly in South Asian and Black 
African-Caribbean populations (Carman et al 2014), and yet ethnic minority 
participation in stroke trials remains surprisingly low.  
 
The inclusion of stroke patients across the whole (severity) scale in research trials is 
important so that results can be applicable to the wider stroke population. Stroke 
severity was noted at the outset of a research approach by Schlegel et al (2003) and 
evaluated using the National Institutes of Health Stroke Scale (NIHSS) – a clinical 
assessment tool used within stroke medicine. The scale has been widely accepted by 
clinical researchers and clinical care professionals due to a high level of score 
consistency and ease of administration with minimal training. 
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Kasner et al (2003) found that a modified version of the stroke severity scale could be 
estimated from a review of medical records. Similarly, Bushnell et al (2001) and 
Williams et al (2000) found that the NIHSS could be reliably estimated retrospectively 
from the admission neurological examination (although actual testing was preferable). 
Developed from work by Brott et al (1989), it has since been repeatedly validated for 
assessing stroke severity and found to be an excellent predictor of patient outcomes 
(Muir et al 1996; Frankel et al 2000).  
 
Weimar et al (2006) analysed 1,725 consecutively admitted acute ischaemic stroke 
patients and found that trial design could be improved in terms of time or study size 
by using defined thresholds for recovery and mortality compared to a fixed inclusion 
criterion of an NIHSS scale. This will be discussed further in the methodology 
chapter. 
 
2.4 Participants and Non-Participants 
Elkins et al (2006), suggest that characterising predictors of recruitment may help 
optimize future trial design. This has cost implications in terms of trial set-up and 
investment of working time for all parties. Shilling et al (2011) call for further 
exploration of those who decline trials and specific research on accessing ‘decliners’ 
as a group to explore reasons for declining trials at different stages of recruitment. 
 
In other disease areas such as cancer, Jenkins and Fallowfield (2000) used a 
communication study (questionnaire consisting of prompts) to assess reasons for 
accepting or declining to take part in cancer therapy clinical trials. Of 204 cancer 
patients eligible for randomised clinical trials, 72% agreed to participate. The most 
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common reason stated for accepting entry was altruism and trust in the doctor.  Of 
the decliners, the main reason stated was also trust in the doctor - which in the 
absence of detailed interview may suggest clinician influence. A preference for the 
doctor choosing a treatment as opposed to randomisation was also highlighted by 
decliners. A higher acceptance rate was noted in a trial which gave active treatment 
in all study arms. This is not surprising given the controversial nature of trial design 
with a no active treatment arm. 
 
Lloyd-Williams (2003) used postal questionnaires with potential heart failure trial 
participants at the time of recruitment. No difference was found in sociodemographic 
characteristics between patients who agreed to participate and those who did not. 
The main reason stated for non-participation was age (too old), health status (too 
unwell) or too busy. Recommendations in light of the findings include clarity of the 
benefits of taking part in a study when unwell and the call for trial designs to take into 
account busy lives for potential participants of all ages. 
 
Avis et al (2006) in a cohort of 208 breast cancer patients, found a 58% participation 
rate across phase I-III trials with phase II trials having a higher acceptance rate. From 
their data, reducing drawbacks, specifically travel time, and improving physician 
communication, were identified as areas to address to increase participation.  
 
In other healthcare areas such as antenatal screening, Koschack (2009) found those 
declining deliberated more deeply on the pros and cons of research participation. 
Interviews were conducted with those who declined and showed personal, diverse life 
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experiences and philosophy in regard to specific tests (Down Syndrome), to be the 
main determinant. 
 
Madsen et al (2007) explored the attitudes to clinical trials in a small group of female 
cancer patients using a grounded theory approach. Patients voiced positive attitudes 
believing trials to be necessary for medical advances. Those agreeing to participate 
argued participation was a moral obligation. Most expressed a discomfort with 
randomisation whilst decliners expressed a radical change in focus at decision time 
and personal choice. Patients support the suggestion that a feeling of hope is 
associated with research involvement (Weiss Roberts et al 2002). 
 
Less well documented in the literature to date are the opinions and attitudes of stroke 
recruits and non-recruits (decliners). There appears to be a gap in the literature 
associated with stroke disease with unclear factors associated with declining 
participation in a research trial when offered. In terms of a level of willingness to 
participate, there may be a proportion of patients that will always decline participation, 
regardless of whether or not these decliners are given further details about the study. 
This number could be factored into trial design for numbers needing to be screened 
for a conversion rate to achieve target recruitment figures and factored into a 
recruitment strategy. 
 
2.5 Reflection on the Literature 
A critical approach through this review has been adopted in order to analyse its 
implications for this study. In this section, the main points are summarised. 
 
 49 
In the first section of this chapter, theories of behaviour were discussed together with 
debates in the literature on predictive behaviour and hypothetical situations. Decision-
making was then reviewed from an individual perspective, cognitive and personal 
biases were noted and information overload was considered. This indicated the 
complexity of factors associated with the decision-making process and how this might 
be further compounded with disease and a need for a recruitment strategy.  
 
Informed consent in the research process was explored and included current findings 
in regard to proxy decision-makers.  Four identifiable components necessary for a 
recruitment opportunity were discussed and influences to this recruitment process 
where noted from the literature to broadly fall into organisational, clinical disease and 
population specific factors. 
 
Disease assessment scales used within the clinical setting were outlined with regard 
to stroke and the most commonly used was explored further.  
 
An absence in the literature was noted in regard to patients declining participation as 
little is known about that potentially very important cohort of the population and results 
in a gap in our knowledge of findings which are generalizable to the population and 
the disease area of interest, as a whole. 
 
Previous literature in relation to low recruitment rates has cited various explanations 
including issues with trial design -extending the time needed to reach recruitment 
target; failure to approach potential participants or identify eligible participants and 
fewer eligible participants than anticipated (McDonald et al 2006); and barriers to 
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recruitment  - potential participant perceptions such as perceived investment of time, 
perceived importance or preference for treatment (Prescott et al 1999).  
 
Little research to date relates to the actual recruitment of stroke patients into acute 
clinical trials (Kasner et al 2009) with factors that may influence potential participants’ 
decision-making about whether or not to participate remaining unclear. Although 
much debated, there is little clear evidence as to why many trials fail to recruit well 
(McDonald et al 2011).  
 
This study arose from the lack of documented literature on the stroke trial recruitment 
process. There is a lack of research characterising potential participants, assessing 
whether particular individuals are likely to take part in or decline research and an 
absence of taught approach strategies for acute stroke research to maximise 
participation in trials.  
  
 51 
CHAPTER 3 
METHODOLOGY 
 
Overview 
This study used survey methods as the primary means of data collection to explore 
patient recruitment into acute stroke trials.  It is the intention that the findings of this 
study will directly inform future practice on trial recruitment. This chapter provides an 
overview of the research methodology (design and methods) and relates this to the 
research question and the purpose of the study. 
 
The first two sections of this chapter outline the research question and the 
methodological considerations that underpin the study design. Section 3.3 provides a 
detailed description of the study design including piloting and site selection, Section 
3.4 describes participant identification and sample size. This is followed by survey 
administration and data collection. Section 3.7 highlights statistical approaches used 
for data analysis.   
 
3.1 Research Question 
The overall aim of this study was to identify the motivators and barriers to trial 
recruitment in order to inform future trial design. This study focused solely on stroke 
disease and more specifically the acute phase post event and the willingness of 
participants to take part in an acute stroke research trial. 
 
Trends in patient characteristics were assessed to decide whether study designs 
could be modified to optimise stroke patient recruitment.   
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The research question was therefore, what influences decision making for clinical trial 
participation in the context of acute stroke and are there any factors which predict  
participation? 
 
3.2 Methodological considerations 
The research strategy employed for this study was a survey administered face-to-
face, with each participant. This approach allowed quantitative information to be 
collected about the population of interest (stroke patients) and decision-making with 
regard to their participation in a clinical trial. The methodological considerations 
underpinning the selection of this technique are outlined in this section. 
 
3.2.1 Paradigm debates 
Social science research is subject to various debates about the epistemological 
issues that underpin it. At its core, these issues come from the philosophy of science, 
which makes basic assumptions about fundamental issues (such as the nature of 
truth) and what it means to know, and beliefs about the way to look at the world. 
These emphasise the approach and the framework which guides such research and 
generally falls into quantitative research versus qualitative measures - although 
according to the literature they are not so mutually exclusive (Niglas 1999). 
 
This study is descriptive research aimed at examining factors associated with a 
situation e.g. the decision-making process associated with participation in a clinical 
trial, in the post stroke acute phase. Factors examined include demographics, 
socioeconomic, health characteristics, behaviour, attitudes, opinions, experiences 
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and knowledge. Descriptive studies estimate parameters in a population and describe 
any associations.  
 
On an epistemological level, the study is positivist assuming objective accounts of the 
world can be generated and values quantitative measures (Sale et al 2002, Smith 
1983). At the alternative end of the spectrum is the interpretivist perspective and 
requires a high validity in qualitative approach. Arguably a purely quantitative 
perspective, maybe insufficient to elicit the full nature of decision-making. By 
incorporating qualitative elements for validity, inferences maybe reportable with 
regard to this.  
 
 
3.2.2 Survey research 
Survey methods are commonly used in health research studies as they enable 
collection of data from large numbers of participants in a standardised format. Data 
analysis allows for statistical associations between responses to specific questions 
and inferences about the wider population can be deducted on the basis of these 
associations.   
 
Survey limitations may include low response rates, the influence of language barriers 
(i.e. a sufficient command of spoken English language is assumed), or literacy issues 
(reading and comprehension ability). In a multicultural society, English may not be the 
first language or spoken at home therefore older relatives may rely on younger family 
members for communication outside of their own language or dialect.  
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Alternative research techniques would have resulted in increased difficulty for 
potential respondents in the cohort population being studied. Responders in the acute 
phase of their stroke would not necessarily have been able to interact sufficiently to 
perform a self-completion survey or participate in qualitative data collection methods 
such as a semi-structured interview on an individual or group basis. Qualitative 
research often takes longer to perform, for data to be collected and involves more 
active participation on the part of participants than a face-to-face administered survey 
(questionnaire).  
 
Patients in an acute phase of illness are likely to have a reduced concentration span 
and be acutely unwell requiring an inpatient hospital stay, so that attending a focus 
group or completing an in-depth interview at the bedside would not be appropriate. 
Additionally, significant rehabilitation maybe scheduled as part of standard care that 
should not be delayed for research. Repeated interactions with the same respondent 
over a period of time were not considered feasible in addition to clinical trial 
requirements and alongside clinical care. 
 
3.2.3 Previous Stroke Studies  
Summers et al (2009) defined the first two phases of stroke as ‘hyperacute’ and 
‘acute’. The ‘hyperacute’ care phase includes pre-hospital and emergency 
department activities, typically lasting for up to 24 hours including the stroke itself and 
transfer to hospital. This is followed by the ‘acute’ care phase that includes the 
admission to hospital and a stay in a critical care unit or stroke unit. Rocco et al 
(2007) found this acute phase to be between 1 and 7 days (commonly up to 72 hours) 
and this phase became the focus for this study. 
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Kasner et al (2009) reported the use of a survey in acute stroke with regard to trial 
participation (discussed in chapter 1, section 1.3). Since the survey element of 
Kasner’s study was conducted with verbal consent, the medical records were not 
accessed and the severity of stroke via NIHSS scoring was not recorded. 
 
Following direct communication with Dr Scott Kasner (Pennsylvania, US), permission 
was granted to adopt that questionnaire with adaptions made for this study for cross-
cultural and comparative purposes, administered in the UK. The limitations of this 
approach are considered in section 3.6. 
 
3.3 Study Design 
This study used a prospective survey tool in the context of acute stroke with two 
integrated components: i) A clinical trial participation decision and ii) a researcher 
administered questionnaire - to identify willingness to participate in acute stroke 
research trials and to elicit reasons why an individual may agree or decline trial 
participation. The study was designed to survey non-responders and decliners to 
acute stroke trials equally with those who chose to participate in a trial. 
 
To minimise the risk of a low response rate and alleviate any concerns of complexity, 
face-to-face administration of the survey was conducted. This approach compensated 
for patients with the inability to read or who were illiterate or for those who had a poor 
command of English (English not being their first language). Additionally, an in-house 
interpretation service was available to help clarify understanding or expression of 
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English where necessary. The survey consisted of a clinical trial participation decision 
and a short questionnaire. 
 
Consideration was given to the length of the questionnaire so as to avoid repeat 
research contacts, respondent fatigue, incomplete answers or disruption to 
rehabilitation and clinical care.  
 
The administration of a face-to-face questionnaire aided the engagement of patients 
to take part as fully as possible under the circumstances of ill health. This approach 
allowed the researcher to assess and adjust the pace of questions according to any 
deficits or effects the patient may have experienced due to the acute event.  
 
Inadvertent mistakes and biases made by the patient were minimised as the 
researcher had the ability to immediately clarify any questions that were unclear or 
caused confusion and equally, repeat answers for accuracy of response. It was felt 
that a self-completed questionnaire would have introduced the possibility of 
inaccuracies, incomplete answers and misunderstanding resulting in unnecessary 
loss of data.  
 
Financial constraints were a consideration in the survey design with no central grant 
funding and an application for NIHR adoption pending. A successful adoption onto the 
NIHR national database would have allowed stroke research network support costs to 
be released and accessed for additional researchers but a rejection would result in no 
additional resources.   
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To capture a decision on clinical trial participation (from all potential participants), a 
mock trial was incorporated into the survey design alongside real trials, open at that 
site. Potential participants eligible for a real trial were offered an opportunity to 
consider a real trial. Patients ineligible for a real trial were offered the mock trial for 
consideration instead. The questionnaire accompanying this trial participation-
decision consisted of a combination of closed questions using Likert scales and some 
open questions (to aid a response close to social reality).  
 
This is similar to the methodology used by Kasner et al (2009) to identify those who 
would participate in acute stroke trials and by Goldstein et al (2010) to evaluate 
willingness to be enrolled in a hypothetical acute stroke trial in the Emergency 
Department (using exception from informed consent), although Goldstein sampled 
consecutive ED attendees whilst Kasner used prospective acute stroke admissions. 
 
For the current study, a valid informed consent process was part of the study design 
with patient information sheets being considered for an adequate length of time 
(participant dependent) although the remit of an acute phase trial (typically within 72 
hours from stroke onset) was stressed, where the recruitment window was short. A 
full consent process was planned. 
 
All questionnaires were administered by a single researcher, which standardised the 
format and made sure that all questions were asked in the same way. The 
questionnaire was administered as soon as reasonably possible after a patient had 
been admitted to hospital noting the time and date of administration as a reference 
point (for delay in seeking help, arrival to hospital and timing of a research approach).   
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3.3.1 Patient & Public Involvement and Piloting 
As the questionnaire had been devised and administered in America, it was adapted 
prior to use in the UK. A patient and public involvement (PPI) group for stroke disease 
were approached early on in study design. The study protocol and associated 
paperwork were reviewed by designated members of the PPI group, providing 
feedback that was incorporated into the final design.  
 
The questionnaire and associated trial paperwork were piloted by 10% (n=20) of the 
proposed final sample size. Several stroke survivors and their families considered the 
documentation at various stages of stroke event (during admission, at discharge and 
in the community) - for appropriateness of wording and ease of understanding. 
Members of NHS staff also reviewed the trial documentation.  
 
The questionnaire was devised to be short with a maximum administration time of 20 
minutes. This was found to be the case and the pilot sample feedback supported the 
length.  
 
At the outset of the questionnaire, all participants were asked to define what they 
understood by the term “clinical trial”. Ambiguity was noted at piloting, surrounding 
respondents’ understanding of this term. Any verbal response that was given was 
recorded verbatim to avoid any interpretation, misinterpretation, bias or guiding. At 
the end of the response, an accurate, official definition of a clinical trial as determined 
by DH, NHS Choices (2015) was given in full and understanding was checked before 
proceeding further with the questionnaire. This was to avert any misunderstanding or 
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misconceptions which may occur if respondents had not had the chance to receive 
clarification. The definition used can be found in Appendix 1. 
 
As a result of the piloting phase, the scale of wellness within the questionnaire was 
reduced from that typically used, from 0-100 to 1-10 as several members of the 
healthy, non-stroke pilot sample highlighted concern that there were too many 
numbers in the range. 
 
The changes as a result of the pilot and PPI feedback were incorporated into the final 
version of the study documents found in Appendix 2 - Survey tool and study 
documentation. These received a favourable ethical opinion from The Black Country 
NRES Committee West Midlands following a full ethics board review (05 March 2012) 
and two NHS Acute foundation Trusts were identified as potential recruiting sites. 
 
3.3.2 Clinical Assessment Tools 
A range of clinical assessment tools are used in the hospital setting for patient 
evaluation and monitoring. These include National Institute of Health Stroke Scale 
(NIHSS); Scandinavian Stroke Scale (SSS); ABCD2 score (used to predict the short-
term risk of a stroke following a Transient Ischaemic Attack - TIA); TOAST criteria; 
Bartel; Rankin and GCS, the latter three not being stroke specific but used in clinical 
practise in relation to patients (including stroke patients). 
 
The NIHSS is a 15-item impairment scale used to evaluate neurologic outcomes and 
degree of recovery for patients with stroke (Appendix 3). The scale assesses level of 
consciousness, extraocular movements, visual fields, facial muscle function, extremity 
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strength, sensory function, coordination (ataxia), language (aphasia), speech 
(dysarthria), and hemi-inattention (neglect) (Lyden et al 1999; 2001). Developed from 
work by Brott et al (1989), it has since been repeatedly validated for assessing stroke 
severity and found to be an excellent predictor of patient outcomes (Muir et al 1996; 
Frankel et al 2000).  
 
Each item is scored from 0 - 2, 0 - 3, or 0 - 4, and untestable items are scored as 
‘UN’. A score of 0 indicates normal performance. Total scores on the NIHSS range 
from 0 - 42, with higher values reflecting more severe cerebral infarcts. Schlegel et al 
(2003) classifying scores as mild (<5); moderate (between 6 and 13) and severe 
(>13). Muir et al (1996) highlights an upper ceiling of scoring in patients with severe 
strokes, as many items may not be testable.   
 
The outcome of a clinician stroke assessment scoring was recorded as it is often 
used within clinical care as an indicator of patient progress, for monitoring any 
changes in condition, real trial eligibility or guiding treatment. This score was added to 
the front of the questionnaire. 
 
An application for NIHR support via adoption onto the national portfolio database was 
submitted but subsequently declined, as an invitation to join NIHR as a non-
commercial partner was declined at that time, by the course-fees funding body for this 
MPhil. 
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3.3.3 Site selection  
The primary recruiting site selected was Heart of England NHS Foundation Trust  - 
Heartlands Hospital which based on validated data, receives approximately 400 acute 
stroke admissions annually (Sheppard et al 2012) and whose local catchment 
population reflects the diversity of the city within which it is based (Birmingham, UK); 
has research activity from NIHR national stroke portfolio of studies (open and 
recruiting) and utilising research nurses integrated in clinical care team. 
 
A second additional recruitment site was identified locally as a back-up should 
recruitment numbers be low or if the primary site experienced unexpected issues. 
This was University Hospital Birmingham – Queen Elizabeth, selected due to 
similarities to primary site in terms of stroke service and size.  Although it was not 
expected that a second recruitment site would be necessary, regional reconfiguration 
of stroke services was planned which could have had a significant impact on the 
study and data collection capacity at the primary recruiting site. Figure 3.1 shows the 
location of the recruiting sites within the West Midlands region. 
 
The number of researchers working on the study was capped to one due to financial 
constraints (funding comprising an MPhil studentship). At the primary site, the 
researcher was considered the principle investigator (PI). At the second site, due to 
substantive employment being elsewhere, a Consultant Neurologist provided 
oversight at the PI level for the research. 
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Figure 3.1 Map of West Midlands Hospital  
 
1: Recruiting Site 1- Heartlands Hospital, Heart of England NHS Foundation Trust, B9 5SS. 
2: Recruiting Site 2- Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation 
Trust, B15 2TH. 
 
  
2 
 
 
1 
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3.4 Participant Selection 
Patients were identified by the clinical care team from a prospective emergency 
department (ED) stroke database, TIA and minor stroke clinic referrals (from ED and 
GPs) and direct patient referrals to the stroke lead nurse on a daily basis (from in-
hospital strokes and GPs).  
 
3.4.1 Inclusion criteria 
 All new acute stroke patients who were admitted to the trust and who were 
deemed both approachable and likely to survive the stroke event (as identified 
by the clinical care team).  
 
3.4.2 Exclusion Criteria 
 Patients who were considered not likely to survive the initial stroke event were 
excluded from the study (as deemed by the clinical care team). 
 TIAs and stroke mimics  
 
3.4.3 Sample Size 
Consecutive patients with a primary diagnosis of stroke were approached within a 15 
month time frame (April 2012-July 2013). Patients were selected as consecutively 
approached as opposed to consecutive admissions, by the researcher and as 
opposed to patients self-selecting to complete the questionnaire, based on the 
(broad) inclusion and exclusion criteria. This approach aimed to result in a 
representative sample and provided an equal likelihood of being approached, with 
findings representative of wider society. 
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With an admission rate of approximately 400 strokes annually, consideration was 
made for recruitment target setting as follows: those potential respondents who may 
decline study consent; local 7 day mortality rates; unable to self-consent and no 
available consultees; too busy with investigations; too ill to approach; those not 
interested; missed by the clinical team and those who declined without stating a 
reason. A proposed recruitment target of 200 was deemed necessary (and 
achievable) to provide 80% power (at alpha = 0.05) to detect a 20% absolute 
difference in the likelihood of trial participation. This was in line with Kasner et al 
(2009).  
 
A consolidated standard of reporting trials (Consort) diagram (Schulz et al 2010) 
describes predicted recruitment figures in order to elicit the final sample size for the 
study and how this was devised (Appendix 4). This notably included 13% of patients 
with a primary diagnosis of stroke (National Sentinel Stroke Audit 2008 HEFT) who 
died within the first 7 days of care and 18% overall who died prior to discharge.  
 
3.5 Survey Tool Administration  
All eligible patients admitted with acute stroke were approached in the first instance to 
consider participating in a ‘real trial’ at the recruiting site, by the clinical care team and 
subsequently were offered this study. A ‘real trial’ was deemed to be a live, openly 
recruiting, acute stroke research clinical trial, with ethical and R&D approvals in place 
at the recruiting site. Nine real trials were available at the start of the recruitment 
period (although some trials were imminently due to close to recruitment). 
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Any stroke admissions ineligible for a ‘real trial’ but deemed by the clinical team as 
approachable (likely to survive the stroke event), were also approached about this 
study and simultaneously asked to consider a mock (hypothetical) trial. It was made 
clear both verbally and written on the patient information sheet where a mock trial 
was used as no deception was intended.  
 
The mock trial was devised by selecting a Clinical Trial of an Investigational Medicinal 
Product (CTIMP) from the acute stroke NIHR national portfolio database. The criteria 
for acceptance onto the portfolio includes having been peer reviewed and deemed 
good quality research. A trial was chosen that was open to recruitment nationally but 
not registered at the primary recruitment site for this study. The trial was anonymised 
as a replica and cleared labelled as a hypothetical trial (a copy of which can be found 
in Appendix 2 – Study documentation). 
 
A full consent process was followed allowing sufficient time for respondents to 
consider the information and make a valid informed choice on participation. 
Participation decisions in response to the trial (real or mock) were recorded, since the 
primary outcome of the study was the trial participation decision. If a patient’s mental 
capacity was affected, preventing them from completing a full consent process, a 
consultee (representative or surrogate decision-maker), usually a relative (who knows 
the person best to be able to verbalise their wishes), was approached and invited to 
take part in this study as the ‘respondent’ i.e. the decision-maker for trial participation 
for the purposes of research. This followed the accepted current practice for stroke 
research with any patients unable to make a valid informed consent decision 
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regarding participation (at the discretion of the clinical care team) and follows the 
Mental Capacity Act (DH 2005) philosophy.   
 
All stroke admissions approached and consented for this study, considered a clinical 
trial (real or mock) and completed the study questionnaire. No further contact as part 
of this study was planned (although any required commitments to a real trial 
remained). A flowchart of the study procedure is summarised in Appendix 5. 
 
Recruitment at the primary site commenced in April 2012 and was analysed monthly. 
The target recruitment figure deviated from the actual recruited figures. This was due 
to changes in ‘real’ trial availability (studies closed or were on hold), ward closures 
were experienced for brief periods (due to Norovirus outbreaks) and no approachable 
admissions had occurred for periods in excess of two weeks at certain times. 
Additionally, a non-interventional trial commenced which competed for the same 
cohort of patients. After six months, the decision was taken to open the second (back-
up) recruiting site and this happened in January 2013 with the same researcher now 
working across both sites. This improved recruitment and completed the study within 
the original time frame. Analysis across both sites was undertaken so that any 
differences in the characteristics of the patient cohort, disease variation and service 
provision between sites could be assessed. 
 
Patients discharged from hospital prior to research contact, were considered lost to 
research and typically included those patients with a short length of stay, transfers out 
of area, transfers for neurosurgical intervention and those misdiagnosed.  Those 
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declining this study outright due to any reason were also considered lost to research 
and were not contacted further. 
 
Any patient who lacked the mental capacity to make a valid informed decision 
regarding participation (at the discretion of the clinical care team) and who did not 
have a carer or relative available, were not approached for this study and were 
deemed lost to research.  
 
3.6 Data Collection 
An anonymised trial number was assigned to each participant for confidentiality of 
information recording. A centrally held file linking codes to names was stored on site 
in a locked filing cabinet for the duration of the recruitment period in order to 
determine if the same respondent completed more than one questionnaire. The 
questionnaires were administered by the researcher, with the respondent answering 
each question and responses recorded directly onto each questionnaire. Sufficient 
time was given for a response and where possible all measures were taken to elicit 
an accurate response. 
 
Two specific, open questions allowed for a series of prompts following an initial 
response. These were part of a qualitative exploration and patient responses were 
recorded verbatim.  
 
A National Institute of Health Stroke Scale (NIHSS) scoring was recorded for each 
patient on the day the patient was approached by research. Where this was 
retrospective (a real trial being offered when the researcher was not available), a 
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recorded scoring from the medical records one day either side of the research 
approach was used (Kasner et al 1999). Where a scoring from the medical records 
was not possible and this could not be obtained from any other source, these data 
were considered missing.  
 
Hospital episode statistics and a local in-house stroke register were checked 
retrospectively for any patients discharged prior to the research exposure. This 
allowed for an accurate record of all research eligible stroke patients admitted during 
the recruitment period and to inform on recruitment overall. Data cleaning was carried 
out to validate stroke diagnosis and determine length of stay, which was entered 
retrospectively. 
 
3.7 Data Analysis 
Data were recorded directly onto the questionnaires (hard copy) and uploaded by the 
researcher into an Excel spreadsheet prior to statistical analysis using SPSS v17.0 
(Statistical Package for the Social Sciences, Chicago, IL).  
 
Descriptive statistics (means and proportion as appropriate to data type) were 
calculated using standard methods. Univariate analysis using 2 sample t tests for 
continuous variables and non-parametric tests (Chi Square) were used for categorical 
variables, for those factors associated with trial participation (ethnicity, educational 
level and gender). Significance was defined as p<0.05. Stepwise multivariable 
analysis explored factors independently associated with a participant’s decision to 
take part in a trial.  
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Thematic analysis (Braun and Clarke 2006) was carried out on the qualitative 
elements of the free text within the survey tool. The data generated was coded for 
theme frequencies to expand the range of the study past individual experiences. This 
allowed for categories to emerge from the data and an interpretation of themes 
supported by the data (Guest 2012). As themes emerged, comparison was made with 
original data and cross-checked for accuracy of original meaning to ensure this had 
not been lost in the theme, by the researcher and a University Professor experienced 
in mixed methods research.  
 
A series of set prompts was used following a verbal reason for trial decision. These 
were preselected from the current literature (Kasner et al 2009; NIH 2012, 2015; 
Healthtalk 2012, 2015). 
 
This chapter has provided an overview of the research methodology, identifying the 
main methodological considerations, the study design and its associated limitations. 
In the next chapter the results of this study are presented. 
 
 
  
 70 
CHAPTER 4 
RESULTS 
 
Overview 
As outlined in the methodology chapter, this study utilised survey research as the 
primary means of data collection. Results from a researcher-administered 
questionnaire and clinical trial uptake are presented together with a thematic analysis 
of data generated from responses given to a free text questions in which respondents 
described their reasons for accepting or declining participation in a research trial. 
 
The first section describes the study participation rate followed by analysis of 
participant demographic and clinical characteristics. Section 4.3 presents the 
quantitative results of the questionnaire using univariate and multivariate analysis. 
The final section presents a thematic analysis together with the codes and themes 
that were generated from analysis of free text responses to open questions on the 
questionnaire.  
 
4.1 Participation Rate 
4.1.1 Site Recruitment Figures 
During the study recruitment period, 300 patients were screened for eligibility for the 
study. Of these, 100 were either not approached for study participation or declined to 
participate. Of the overall stroke admissions (n=670), 18% (n=120) were deemed too 
unwell to approach at that time, either by clinical team or having died prior to 
screening. 13% (n=87) of the overall stroke admissions died prior to discharge.  
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Of the 300 screened admissions, five direct approaches were declined by potential 
respondents without a reason being stated and a further two did not have a consultee 
available (and were not able to consent to the study themselves). The remaining 76 
were either imminently being discharged, too busy with treatment or missed by a lack 
of researcher resource. Those with a short length of stay (LOS) of <48 hours, did not 
meet the criteria for an acute study and are included in those missed by the 
researcher. (Figure 4.1: Consort diagram of recruitment). 
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 Figure 4.1: Consort diagram of recruitment to the study 
 
 
 
 
 
Therefore, from 300 patients screened for inclusion, 207 (69%) were approached of 
whom 200 respondents (67%) from two Foundation Trust Hospitals in the West 
Potentially eligible  
(n = 670) 
 
Screened (n = 300) 
45% 
 
Not approachable 
 (n = 17) 
Too unwell as deemed 
by clinical team. 
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(n = 76) 
Researcher Resource 
Ready for discharge 
Too busy with treatment  
Recruited (n = 200) 
30% of those 
potentially eligible 
 
Not eligible (n = 2) 
No Consultee (n=2) 
Discharged prior 
to Study screening 
(n=370) 55% 
LOS < 24hours 
Researcher resource  
Died prior to screening 
 
Declined Study 
(n = 5) 
No reason given (n = 5) 
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Midlands: Birmingham Heartlands Hospital (112 participants), and the Queen 
Elizabeth Hospital (88 participants) completed the questionnaire. Recruitment lasted 
for 15 months in total with an overlap of both sites actively recruiting simultaneously in 
the final 7 months.  
 
Respondents comprised 112/437 (26%) stroke admissions at the Heart of England 
NHS Foundation Trust - Birmingham Heartlands Hospital (BHH) (Figure 4.2) over a 
period of 15 months and 88/233 (38%) stroke admissions at University Hospitals 
Birmingham, Queen Elizabeth (QE) (Figure 4.3) over a shorter recruitment period of 7 
months. The denominators comprised admissions coded using International 
Classification of Disease ICD codes I61, I63 and I64 (RCP 2006).  
            
 
The time of stroke onset was known in 141 (70.5%) cases. For the majority of these 
(n=94), admission was outside of office hours (9-5) and at weekends. A third of 
respondents with a known onset time (n=47 of 141) had the stroke event during 
normal office hours.  
 
26 out of 200 respondents (13%) woke in the morning with a stroke (‘wake-up 
stroke’), having gone to bed the night before, (last seen) well. Of these, 19 (73%) 
Non-
particip
ants 
74% 
Particip
ants 
26% 
Figure 4.2: Percentage of 
Admissions Participating in 
Study from BHH 
Non-
particip
ants 
62% 
Partici
pants 
38% 
Figure 4.3: Percentage of 
Admissions Participating in 
Study from QE 
 74 
were able to self-consent to research whilst seven had to use a consultee. In terms of 
stroke severity, of the 26 ‘wake-up’ stroke patients, four were rated on NIHSS as 
severe. This was increased slightly to six when ‘severe’ was self-rated for (perceived) 
stroke severity.  
 
4.1.2 Decision-maker 
Consent for study participation was made by stroke patients themselves in 138 out of 
200 cases (69%). The remaining 62 patients had a consultee as proxy decision-
maker who responded to the questionnaire on their behalf (14 spouses, 40 children, 1 
sibling and 7 others). 
 
All 200 respondents considered taking part in a clinical trial (real or mock) alongside 
completing the questionnaire. A real clinical trial was offered to 72 respondents (36%) 
whilst 128 (64%) considered a mock, hypothetical trial.  
 
Consultees were more likely to be decision-makers in more severe strokes: 84% 
(n=38) as rated as severe on NIHSS. However, this was not found to be the same for 
severe stroke as rated by self-perceived severity - where the majority of patients were 
able to consent themselves (53%) and consultees were the decision-makers in 47% 
(n=30) of cases.  
 
128 (68%) respondents agreed to participate in a clinical trial of any sort (real or 
mock) with the remaining 72 (36%) declining any clinical trial. Patients who were able 
to consent for themselves were more likely than consultees to agree to trial 
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participation (as shown in Figure 4.4 and 4.5 below), although this difference was not 
statistically significant (X2 = 0.48, p=0.488). 
      
 
The time given for decision-making in an acute trial was determined by the protocol in 
a real trial and a comparative recruitment window for the mock. These followed the 
timings of the acute phase noting any delay in hospital presentation. Overall, 85.5% 
of respondents (n=171) deemed that the amount of time they had been given was 
‘enough’ and ‘more than enough’ time to make a decision on participation. Of these 
respondents, 69% (n=118 of 171) agreed to trial participation. Eighteen respondents 
reported ‘not enough time’ to consider the trial but six of these respondents still 
agreed to participation. Five respondents reported ‘barely enough time’ and four of 
these still agreed to participation (summarised in Table 4.1). 
 
Table 4.1 Perception by respondent of time to consider a Clinical trial 
Time to consider (n= 200) * Agreed to a trial 
n 
Declined a trial 
n 
Not enough (18)                9% 
Barely Enough (5)            2.5% 
Enough (146)                   73% 
More than Enough (25)   12.5% 
 
6 
4 
98 
20 
12 
1 
48 
5 
* Percentages may not total 100 due to missing responses 
 
 
91 
66% 
47 
34% 
Figure 4.4: Patient response  
to trial participation 
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37 
60% 
25 
40% 
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4.2 Participant Characteristics 
A summary of participant demographic and clinical characteristics is shown in Table 
4.2.  There was an even split in the gender of the respondents. 128 respondents 
agreed to participate in a clinical trial out of 200 respondents in this study. Of those, 
male respondents were found to be slightly more inclined to agree than their female 
counterparts (68 vs 60). Stroke patients were able to decide for themselves in 138 
cases (69%) - with an average age of 66 years.  
 
The age of the decision-maker was noted to follow a ‘normal’ distribution graph 
(Figure 4.6). The distribution of age range of the full 200 respondents can be viewed 
on the histogram below (figure 4.5). Participant ages ranged from 28 to 92 years with 
a mean age of 63.4 years. Decade groupings for analysis by age were used. No 
statistical significance was found between age and trial participation.  
 
Figure 4.6: Histogram of Age range distribution of respondents 
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Almost half of the respondents (45% n=90) did not know the type of stroke event that 
had occurred (unable to recall personal knowledge) and no significant difference was 
found between stroke type and the likelihood that a respondent agreed or declined to 
participate in a trial. 
 
No significant differences were found between any of the demographic or clinical 
characteristics and the likelihood that a respondent agreed or declined participation in 
a trial, with the exception of perceived severity of stroke. Participants in the study who 
perceived the severity of stroke to be either moderate or severe were significantly 
more likely to agree to participation in a trial than those who perceived the stroke to 
be mild. 
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Table 4.2 Summary of Characteristics Associated with Trial Participation 
Participant  
Characteristic (n= 200) * 
Agreed 
to a trial 
n 
Declined 
a trial 
n 
p value  
(X2 test for 
association) 
Gender 
Female (99)   49.5% 
Male (101)     50.5% 
 
60 30% 
68 34% 
 
39 20% 
33 17% 
0.399 
 
Age group (Yrs.) 
<50        21.5% 
50-59     17.5% 
60-69     22% 
70-79     20.5% 
>/=80     18% 
 
30 15% 
24 12% 
25 13% 
29 15% 
20 10% 
 
13   7% 
11   6% 
19 10% 
12   6% 
16   8% 
0.268 
Ethnicity 
White (164)         82% 
Non-white (36)    18% 
 
106 53% 
22  11% 
 
58 29% 
14   7% 
0.842 
 
Educational level 
A level/GCSE and below (161)  80.5% 
Degree and Postgraduate (39)  19.5% 
 
101 51% 
27   14% 
 
60 30% 
12   6% 
0.566 
 
 
Deprivation quartile 
Quartile 1 - Most affluent (8)       4% 
Quartile 2 - Less affluent (34)     17.5% 
Quartile 3 - More deprived (45)   23% 
Quartile 4 - Most deprived (107) 55% 
 
4     2% 
18   9% 
32 16% 
71 37% 
 
4     2% 
16   8% 
13   7% 
36 19% 
0.212 
 
 *Percentages may not total 100 due to missing responses 
 
Severity of stroke (perceived) 
Mild (74)          37% 
Moderate (54) 27% 
Severe (64)     32% 
Not sure (8)      4% 
 
39 20% 
36 18% 
45 23% 
8     4% 
 
35 18% 
18   9% 
19 10% 
0 
0.031 
 
Stroke type (personal knowledge) 
Ischaemic (77)      39% 
Bleed (31)             15.8% 
Don’t know (88)    44.9% 
 
48 24% 
16   8% 
61 31% 
 
29 15% 
15   8% 
27 14% 
0.249 
Trial type considered 
Real (72)       36% 
Mock (128)    64% 
 
62 31% 
66 33% 
 
10   5% 
62 31% 
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4.2.1 Ethnicity 
The 2011 census showed that non-white minority ethnic groups comprised 14% of the 
UK population (Office for National Statistics, 2011). This proportion was the same 
across the West Midlands region, but this study saw a higher proportion of 
respondents with non-white ethnicity than both the national and regional average 
(18%, n=36). A comparison of this variation is shown in Table 4.3. 
 
Table 4.3 Comparison of Ethnic Diversity 
Ethnicity England&Wales* 
2011 (%) 
WestMidlands* 
2011 (%) 
This Study 
2012 (%) 
White 87 86 82 
Mixed / Multiple Ethnic 
Groups 
2 1 1 
Asian: Indian 3 4 3 
Asian: Pakistani 2 4 8 
Asian: Bangladeshi 1 1 1 
Asian: Other 1 1 4 
Black: African 2 1 1 
Black: Caribbean 1 2 4 
Black: Other 0 - - 
Other Ethnic Groups 1 - - 
*Source: Office for National Statistics, 2011 Census data from KS201EW. 
 
 
4.2.2 Educational level  
The highest level of taught education received by respondents was recorded within 
five sub categories ranging from: no formal qualifications (including school leavers 
certificate); GCSE / CSE / O level; A level or equivalent; Degree or vocational 
qualifications and postgraduate studies. For comparison of proportions analysis, a 
binary grouping was created, comparing those with degree or higher-level education 
to those with A-Level/GCSE level education and below.  No significant association 
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was found between an individual’s level of education and whether or not they agreed 
to participate in a trial. 
 
4.2.3 Socioeconomic deprivation  
Deprivation quartiles were derived using the online tool GeoConvert. This tool uses 
residential postcodes to associate each individual with their specific electoral ward, 
with each ward (n=32,482 across England) ranked according to its position in the 
2010 Index of Multiple Deprivation (IMD). This allows each individual to be assigned a 
deprivation quartile on the basis of his or her place of residence.  Quartile 1 
represents the most affluent group, and quartile 4 the most deprived group.  
 
Six of the 200 study respondents could not be assigned a deprivation quartile. Of the 
remaining 194 respondents, over half (n=107) lived in areas within the most deprived 
quartile (Figure 4.7). No association was found between trial participation and 
socioeconomic deprivation. 
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Figure 4.7: Socioeconomic deprivation 
 81 
4.2.4 Stroke Severity measures 
Stroke severity was measured using the National institute of Health Stroke Scale 
(NIHSS) at the time of the research approach either prospectively or extracted from a 
patient’s medical records +/- one day either side of that date.  
 
This was compared to a self-assessed severity measure made by the person giving 
consent to the study (patient or consultee). Figure 4.8 shows the distribution of 
NIHSS scoring recorded for patients as part of this study, in comparison to Figure 4.9 
that shows the distribution of self-assessed stroke severity by respondents (decision-
makers). 
 
In Figure 4.8, 93 (46.5%) patients were assessed as having had a mild stroke (NIHSS 
0-5), 58 (29%) were assessed as moderate (NIHSS 6-20) and 45 (22.5%) were 
assessed as severe (NIHSS >20). Four respondents did not have a NIHSS score 
recorded. 
 
 
*Mild, moderate and severe categories of NIHSS scoring defined by Ver Hage (2011). 
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Figure 4.8: Clinician assessed severity scoring  
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By comparison (in Figure 4.9), 74 (37%) patients were self / consultee rated as 
having had a mild stroke, 54 (27%) were self / consultee rated as moderate and 64 
(32%) were self / consultee rated as severe. Eight respondents were unsure as to 
how to rate the current condition. 
 
 
 
Although respondents were more likely to view the stroke as more severe than the 
NIHSS score, there was no statistically significant difference between clinician and 
self-assessed stroke severity scoring although the p value approaches significance 
(X2 = 5.58, p=0.061). There was no statistically significant difference between 
whether or not a respondent agreed to participate in a trial on the basis of NIHSS 
scoring. However, respondents who self-rated stroke severity as moderate or severe 
were significantly more likely to participate in a trial than those who considered the 
stroke to be mild (X2 = 9.87, p=0.031). The likelihood of agreeing to participate in a 
trial was increased as perceived stroke severity increased using Chi square for trend 
(X2 = 4.674, p=0.031). 
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From the data, some patients reported stroke severity as severe and yet clinician 
scoring on NIHSS was mild. This is illustrated in Figures 4.10-4.12. The red column 
represents the total numbers of respondents rating themselves as that particular 
severity. The blue columns alongside are not additional respondents but a 
disaggregation of the tall red bar. For each self assessed severity (red, tall bar), the 
corresponding NIHSS rating is shown (blue bars). 
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Figure 4.10: Self-assessed: Severe  
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Figure 4.11: Self-assessed: Moderate 
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4.2.5 Length of Hospitalisation  
A comparison was made between the timing of the research approach and the length 
of time a patient remained in hospital (Figure 4.13). 42% of respondents were 
approached within 48 hours of admission (n=85). A delayed approach (i.e. 
approached more than 48 hours after admission) occurred where respondents were 
initially ‘too unwell’, awaiting a consultee, busy with treatment, delay in presentation 
and out of hours presentation in some cases i.e. over a bank holiday weekend.  
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Figure 4.12: Self-assessed: Mild 
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4.3 Questionnaire responses 
At the beginning of the survey, respondents were asked to define the term ‘clinical 
trial’. Three per cent were able to define the term in line with the DH official definition. 
Eighty-five per cent made an attempt using one-two key words from the official DH 
definition. Eleven per cent (n=23) were unable to proffer any answer as highlighted in 
Figure 4.14. 
 
 
 
4.3.1 Attitudes and opinions 
Seventeen respondents (8.5%) rated their general attitude to clinical trials as being 
‘very positive’, and 115 (57.5%) rated their attitude as ‘positive’. Of these 132 patients 
who rated their attitude as positive and very positive, 94 (71%) agreed to participate 
in a trial. A neutral attitude was expressed by 26% (n=52), although over half of these 
(61.5%) still agreed to trial participation. A negative attitude was reported by 16 
respondents (8%), although one of these went on to agree to a trial (Figure 4.15). 
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Attitude to clinical trials was strongly associated with participation in the clinical trial (p 
for trend <0.0001). Respondents who had a positive or very positive attitude to clinical 
trials were significantly more likely to participate in a trial than those who had a 
neutral or negative attitude (74% vs 26%, p<0.0001). 
 
4.3.2 Prior knowledge of research consequences  
Over one third of respondents (n=72) were aware of having heard a consequence of 
participating in a clinical trial (whether positive, negative or both) as shown in Figure 
4.16. Overall, 18% (n=36) of total respondents were aware of having heard positive 
consequences of clinical trials previously from an outside source (i.e. media, 
newspapers or friends) whilst 5.5% (n=11) reported having heard negative 
consequences from an outside source. 12.5% (n=25) of respondents were aware of 
having heard both positive and negative consequences of clinical trials previously. 
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4.3.3 Health Status 
Respondents were asked to score their level of health pre-stroke and post event (at 
the time of the study approach) with a top score of 10 reflecting excellent health and a 
drop in points denoting a decline in perceived health status following stroke. A drop in 
self-reported health scoring post stroke compared to their pre-stroke rated health was 
reported by 179 respondents – with a 1 point drop represented as -1 on Figure 4.17 
up to a 9 point drop in health scoring, represented as -9; 13 respondents reported the 
same level of overall health (a zero point drop) and 7 reported an improvement, – 
citing the treatment of co-morbidities (represented as a positive number on the 
horizontal axis). Negative numbers on the horizontal axis correspond to the number of 
points dropped in health scoring since stroke event. The mean and mode was a 3-
point drop in overall health state due to stroke (52%) as seen in Figure 4.17.  
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188 respondents had risk factors associated with stroke in their past medical history 
with two risk factors being most common. Three quarters of the respondents had at 
least two risk factors increasing their risk of having a stroke or second stroke (Figure 
4.18). 
 
 
 
The most common co-morbidity was high blood pressure (HBP). The proportion of 
respondents with HBP that agreed to take part in a clinical trial was higher than 
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expected in comparison to other co-morbidities although this was not statistically 
significant (p=0.322). Of the total respondents with high blood pressure (n=129), 80 
agreed to take part in a trial (Figure 4.19). 
 
In addition to one of the real trials being a blood pressure drug trial, the mock trial was 
also a blood pressure, drug trial and was considered by 128 respondents of the total 
200.  
 
 
 
12% of respondents (n=24) had been approached about taking part in research 
before (prior to this admission). Of these 24 approached, 20 had consented and 
participated in a research trial before. Of these 20, half (n=11) agreed to a clinical trial 
as part of this study. 
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4.3.4 Decision  
Sixty per cent (n=120) of respondents made a decision regarding participation without 
consulting anyone else. Of these, almost half (43%, n = 52) stated that they would 
have liked to have discussed it with a family member if the opportunity had been 
available.  
 
In terms of what influenced people in their decision as to whether or not to participate 
in a trial, ‘self–determined decision’ was cited as the biggest influence on decision to 
take part, with 174 respondents (87%) citing that ‘self’ was a ‘strong’ or ‘very strong’ 
influence on their decision-making. The next most commonly cited influence on 
decision-making was family or friends, which was mentioned by 66 respondents as 
being a ‘strong’ or ‘very strong’ influence.  
 
The questionnaire included some open questions in which respondents were asked to 
elaborate on the reasoning behind their decision-making on accepting or declining 
trial participation. These responses to open questions were analysed thematically 
(see section 4.5). Subsequently, prompts as to the reasoning behind the decision to 
participate were categorised (Kasner et al 2009; NIH 2012, 2015; Healthtalk  2012, 
2015)  
 
Figures 4.20 and 4.21 highlight the prompts used following agreement to participate 
in a trial. The majority of those agreeing to participate in a trial, did so based on 
feeling happy with the information, to help others, keen to be included and potential 
for a new treatment.  
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The majority of respondents agreeing to take part in a trial, did not agree based on 
previous experience (which correlates to the small number (n=24) of those 
respondents having considered research prior to admission).  
 
Respondents were split more evenly on prompts regarding possibility of better care, 
timing of when asked, to help medical staff who asked them and something in the trial 
that was liked (Figure 4.21). 
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Figures 4.22-4.24 highlight those prompts used following a decline to participate in a 
trial. More respondents declined a trial citing it to add more stress, there was 
something in trial they didn’t like, a fear of a drug reaction or adverse reaction and 
having different priorities at the time of asking.  
 
A much closer split (almost 50:50) was found with those declining due to not wanting 
to be a ‘guinea-pig’ (self-perceived) and that it might not help the current stroke 
(Figure 4.22). 
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For those respondents who declined participation in a trial, the majority did not 
decline because of not being told the outcome of the research, randomisation or 
reluctance to invest the time (Figure 4.23). 
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time to make a decision, that they couldn’t take in the information or the timing they 
were asked (although a small numbers did quote these on prompting as possible 
reasons (n=15, 19 and17 respectively – Figure 4.24).  
 
 
 
 
Of those declining a trial, three respondents were happy to agree to participation at a 
later date citing wrong timing earlier on in admission when originally approached as 
they ‘did not know what was going on’.  
 
One consultee had a choice of two real trials and reported: “…a terrible dilemma in 
the choice, more than just the research – which was bad enough”. The consultee 
went on to choose the second trial involving interventional scans (real trial) stating 
clear rationale as to declining the first due to specific interventional drugs, “... I don’t 
like the thought of agreeing for him to have medication, I don’t like medication”. 
(Consultee – Patient’s daughter, aged 33 years). 
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4.4 Univariate and multivariate analyses 
Univariate and multivariate binary logistic regression analyses were carried out to 
assess which variables were associated with agreement to participate in a trial (real 
or mock) – the result of which are summarised in Tables 4.4 and 4.5 respectively. 
 
4.4.1 Univariate analysis 
Respondents who perceived their stroke as mild were around half as likely to agree to 
participate in a trial than patients who perceived their stroke as severe (odds ratio 
(OR) 0.47, 95% confidence interval (CI) 0.23-0.95; p = 0.036). Respondents who 
were offered a real trial were almost six times more likely to participate in a trial than 
those who were offered a mock trial. (OR 5.73, 95% CI 2.70-12.17; p < 0.0001). 
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Table 4.4 Univariate analyses 
Variable Variable P value Odds ratio 95% CI 
Gender 
Male 0.277 1.38 0.77 to 2.47 
Female Reference - - 
Age 
<50 0.148 2.00 0.78 to 5.11 
50-59 0.335 1.60 0.62 to 4.16 
60-69 0.910 1.05 0.43 to 2.56 
70-79 0.170 1.93 0.76 to 4.95 
80+ Reference - - 
Ethnicity 
White 0.842 1.08 0.51 to 2.30 
Non-white Reference - - 
Education 
Lower 
attainment 
Reference - - 
Higher 
attainment 
0.336 1.48 0.67 to 3.29 
Deprivation 
Affluent 0.356 0.51 0.12 to 2.15 
Less affluent 0.220 0.61 0.28 to 1.35 
More deprived 0.567 1.25 0.58 to 2.67 
Most deprived Reference - - 
Perceived 
stroke 
severity 
Mild 0.036 0.47 0.23 to 0.95 
Moderate 0.781 0.89 0.41 to 1.97 
Severe Reference - - 
NIHSS stroke 
score 
Mild 0.789 1.11 0.53 to 2.29 
Moderate 0.345 1.48 0.66 to 3.35 
Severe Reference - - 
Respondent 
type 
Patient 0.358 1.34 0.72 to 2.48 
Consultee Reference - - 
Trial offered 
Real <0.0001 5.73 2.70 to 12.17 
Mock Reference - - 
*Bold entries denote statistically significant p values 
 
4.4.2 Multivariate analysis 
Findings from the multivariate analyses are highlighted in Table 4.5. The following 
univariate variables were included in the model: gender, age, ethnicity, education, 
deprivation, perceived stroke severity, NIHSS stroke score, respondent type and trial 
offered. 
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Once other variables had been controlled for, ethnicity was statistically significant with 
respondents of white ethnicity being around three times more likely than non-white 
respondents to agree to participate in a trial (OR 3.29, 95% CI 1.03-10.51; p= 0.045). 
 
Respondents whose stroke severity was mild on NIHSS scoring were significantly 
more likely than those who were severe on the NIHSS to agree to trial participation 
(OR 4.97, 95% CI: 1.10-22.51; p = 0.037), although this result should be interpreted 
with caution due to small numbers and the large confidence interval. 
 
Similarly, as found in the univariate model, the type of trial that a respondent was 
offered was a significant predictor of their likelihood of agreeing to participate. 
Respondents offered a real trial were almost ten times more likely to agree to 
participate than those who had been offered a mock trial (OR 9.45, 95% CI: 3.70-
24.16; p < 0.0001).  
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Table 4.5 Multivariate analyses 
Variable Variable P value Odds ratio 95% CI 
Gender 
Male 0.302 1.51 0.69 to 3.30 
Female Reference - - 
Age 
<50 0.382 1.74 0.50 to 6.02 
50-59 0.770 1.20 0.35 to 4.08 
60-69 0.532 0.69  0.22 to 2.19 
70-79 0.148 2.40 0.73 to 7.85 
80+ Reference - - 
Ethnicity 
White 0.045 3.29 1.03 to 10.51 
Non-white Reference - - 
Education 
Lower 
attainment 
Reference - - 
Higher 
attainment 
0.156 2.03 0.76 to 5.41 
Deprivation 
Affluent 0.602 0.57 0.70 to 4.67 
Less affluent 0.061 0.37 0.13 to 1.05 
More deprived 0.476 1.38 0.57 to 3.37 
Most deprived Reference - - 
Perceived 
stroke 
severity 
Mild 0.001 0.12 0.04 to 0.42 
Moderate 0.055  0.34 0.12 to 1.03 
Severe Reference - - 
NIHSS stroke 
score 
Mild 0.037 4.97 1.10 to 22.51 
Moderate 0.250 2.17 0.58 to 8.13 
Severe Reference - - 
Respondent 
type 
Patient 0.999 1.00 0.32 to 3.09 
Consultee Reference - - 
Trial offered 
Real <0.0001 9.45 3.70 to 24.16 
Mock Reference - - 
*Bold entries denote statistically significant p values 
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4.5 Thematic analysis  
Of those respondents agreeing and declining a trial, the factors stated in the open 
questions for decision-making (prior to any prompt) were analysed thematically. 
 
4.5.1 Agreed to participate 
During the thematic analysis, codes emerged for respondents agreeing to participate 
in a clinical trial (64% of respondents) and from these, two common themes arose:  
 Altruism - of self and for others in the future with altruism expressed as well as 
self-concern.  
 Ambivalence - within which inevitability was also cited. 
 
4.5.1.1 Altruism 
Respondents who were happy with the trial and keen to take part were included in 
this theme. An example of responses included the following: 
“…was so pleased to do it, to help people the same as me”. (Patient, aged 65 years – 
became very emotional); 
“…if it will do me any good…” (Patient, aged 83 years). 
 
Altruism for the greater good and wanting to help others in the future was cited by 
respondents in a large number of cases, in isolation and amongst a group of reasons 
given for a decision to participate. Self-concern incorporated a rationale for decision-
making of better care and respondents highlighted ‘extras’ in a trial as being 
influential in reasoning behind the decision i.e. an ultrasound scan being available 
when it is not part of routine clinical care and a perception of receiving more 
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monitoring by the hospital if choosing to take part in research trial. An example of 
responses included the following: 
 
“…Information from nurse was very positive. Keen for anything that would help him, 
that he would be monitored, regular scans, less likely to get clots because of it.…” 
(Consultee, aged 52 years); 
“…thought it would help me and others in a situation like mine at a later stage in the 
future. I'm an example. So many things we don't know about. I had been asking the 
question myself about oxygen…”. (Patient, aged 52 years in regard to the Oxygen 
trial). 
 
4.5.1.2 Ambivalence 
This included the perception that research was necessary, respondents who felt there 
was nothing to lose or were ‘not bothered’, for example: 
 
“…As long as doesn't interfere with current meds. Provided Dr was in support of it”.  
(Patient, aged 88 years); 
“…I don't know why actually…” (Patient, aged 74 years). 
 
A series of reasons were given by some respondents which overlapped these themes 
such that ambivalence was expressed prior to altruism, for example: 
 
“…younger person may say no but at 87, I've lived my life so if my body is in a fit 
state, I'd do it, keen to give something, happy if it might help someone else.” (Patient, 
aged 87 years). 
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There was a perception that things could not be worse or trial was harmless, Learning 
and where new knowledge could be gained or work to prevent future strokes was also 
within this theme. One response being: 
“…. no reason to say no, good explanation by the nurse…” (Consultee, aged 54 
years, agreed to patient participating in a clinical trial).  
 
4.5.2 Declined to participate 
During the thematic analysis, codes emerged for respondents declining patient 
participation in a clinical trial (36% of respondents) and from these, three common 
themes arose:  
 Trial related 
 Disinterest 
 Overwhelmed  
 
4.5.2.1 Trial related 
Trial related issues included concern regarding the trial medication (drug study), 
follow-up regime, concerns regarding comorbidities and concomitant medication, risk 
of making things worse, no guarantee and worry about side effects’. For example: 
 
 “…Because patient would refuse if able to self consent. Doesn't like taking 
medication - irrelevant of patch.…”. (Consultee – patient’s daughter, aged 54 years). 
 
Six respondents volunteered information, unprompted in hindsight, regarding timing of 
research trial approach for example: 
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“…if you’d have asked me in A&E, I would have said no as I didn’t know what was 
going on …. but today is better… so yes”. (Patient, agreed to clinical trial, aged 72 
years). 
 
“…I will do anything I think will help. If 100 years ago, nobody had said yes to 
anything, where would we be now? Would say no to drug trial though until I know 
what is really going on with this stroke, I wouldn't. It’s the unknown of how the stroke 
will keep affecting me.” (Patient, declined a clinical trial, aged 65 years). 
 
4.5.2.2 Disinterest 
Disinterest included those directly expressing “not interested” and reporting an 
unclear recovery pathway; those ineligible, unsuitable or too unwell were incorporated 
here. Age responses were also incorporated here and were highlighted by both 
patients and consultees.  
 
“…I believe in research, if I was younger…now set in my ways. If it was just questions 
and answers then would say yes but due to age…no”.  (Patient, aged 72 years); 
 “…Not to say wouldn't if he was more improved. Not fit enough because of what’s 
happened to him.  Perhaps slightly younger people less than 70…” (Consultee – 
patient’s wife, aged 81 years); 
 “…I think I'm too old, I think it’s a good thing. Not at the moment…”. (Patient, aged 90 
years); 
 “…she’s old school, if it’s not broke, don’t try and fix It...” (Relative’s perspective of 
patient’s approach to life. Consultee – Patient’s son, aged 47 years, declining 
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patient’s participation in a clinical trial. Patient had a reported stroke severity as 
severe by consultee and severe category of NIH Stroke scoring by clinician).  
 
4.5.2.3 Overwhelmed 
Feeling overwhelmed was a common theme relating to: ‘too much on’ (overall) and 
‘too much to take in’, ‘been through enough’, ‘got enough on already’.  A response of 
being ‘too unwell’ and related to ‘stroke severity’ was also incorporated here. For 
example: 
 
“…At that time (acute stroke) I was 'not in the right place' to make a decision. You 
don't hear about it (research) so you're not prepared. Unfamiliarity. Felt patient was 
too poorly - saying no meant one less thing to worry about. Knew needed to make a 
quick decision, not ready to make that decision”. (Consultee - daughter, aged 52 
years, consulted with six family members). 
 
The results of this study have been presented using descriptive statistics and a 
thematic analysis.  These results will now be discussed in the next chapter. 
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CHAPTER 5 
DISCUSSION 
 
Overview 
Difficulties exist with carrying out clinical trials in the NHS. These difficulties are 
compounded in the acute environment and even more so in the context of an acute 
neurological injury within emergency care. Patients in the acute setting have the most 
to benefit from research and yet the least amount of time to consider it. An already 
challenging time for a research opportunity to be considered, is further complicated in 
the presence of an acute event with associated fluctuating symptoms, unclear 
diagnosis, uncertain prognosis and potential variation in mental capacity requiring the 
need for a consultee.   
This study set out to document the willingness to participate in acute stroke studies by 
patients or their consultees and has captured public opinion prospectively in regard to 
a clinical trial participation decision in an acute setting, for 200 respondents acutely 
affected by stroke. 
The findings of this study are considered in the first two sections of this chapter and 
are discussed in reference to recruitment and influencing factors on decision-making. 
Comparison with the current literature is made throughout the chapter. Section 5.3 
considers the strengths and limitations of the chosen methodology in light of the 
research findings. In the final section, the potential impact on evolving trial design and 
recruitment strategies is discussed in light of the original aim and objectives of this 
study. 
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In summary, the findings of the study include a comparison of site characteristics and 
participant characteristics. Results suggest a disparity in participation-decision 
outcome depending on: whether patients consent themselves and if an affinity to a 
trial is perceived. A difference was found in participant’s willingness to join a trial 
based on whether it was real or hypothetical. Self assessed stroke severity differed 
from clinician assessment using an assessment tool and was statistically significant in 
that worsening severity (as self-assessed), increased the likelihood of trial 
participation. Results from multivariate analysis include some additional significance 
for ethnic minority representation. Quotes were used from a thematic analysis that 
reflects the common themes determined for trial participation-decision outcomes.  
 
5.1 Recruitment 
5.1.1 Site characteristics 
Recruiting sites admitted stroke patients in keeping with national data sets for basic 
demographic details and stroke type. Both offered similar clinical services (RCP 
2014b). Both sites accepted a similar catchment number of patients from their local 
population and were six miles apart. The first recruiting site had an onsite 
rehabilitation ward for treatment after the acute phase and had a thrombolysis service 
operating during weekday office hours only, diverting stroke admissions for 
assessment outside of these times to a partner hospital within the same trust seven 
miles away. Patients were transferred following the hyperacute phase to spend the 
acute phase in the recruiting site if their registered GP was in the ‘catchment’ area for 
that site.  
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The second recruiting site had an on-call thrombolysis service for out of hours with all 
patients received at that site at any time. Patients were transferred to a community 
trust for further rehabilitation (six miles away) after the acute phase and once a bed 
became available. This resulted in a length of stay variation between the two 
recruiting trusts but consistency was maintained in the research approach since the 
acute phase was the focus for this study and both recruiting sites treated the patients 
during this phase. 
 
If a research contact was missed during admission, patients re-attended at a 6 week 
follow-up clinic appointment which was a potential opportunity to increase 
recruitment. However, this was after a considerable length of stay in some cases and 
patients were not able to recall sufficient details about their time in the acute 
environment to take part in the study. The mock trial was not appropriate at this time 
point as it reflected acute treatment and this would have been a retrospective 
decision, opposing the prospective nature of the study design. As a result, any 
patients discharged before a research contact, were not recruited. MacNeill et al 
(2013) found patients didn’t distinguish between clinical care and research study. This 
was confirmed in ad hoc discussions with patients outside of the formal study.  
 
5.1.2 Participation 
The study population was diverse and the study achieved higher ethnic minority 
representation than regional and national population figures (Office for National 
Statistics, Census 2011). The stroke population studied typically reflected national 
statistics in all other respects, i.e. age, gender and educational level (RCP 2014a). 
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Research in the literature suggests willingness to participate in a hypothetical (mock) 
trial to be a valid predictor of actual participation (Halpern et al 2001). Assessing 
responses in a hypothetical situation as opposed to an emergency may reflect true 
opinions and preferences. However, the researcher for this study noted initial 
confusion in some respondents, with the concept of a hypothetical trial in itself being 
the focus of consideration as opposed to the details of the trial. Of the 200 
respondents in this study, 36% (n=72) considered a real trial and 64% (n=128) 
considered a hypothetical trial.  
 
Univariate analysis found respondents were six times more likely to participate in a 
real trial than a mock trial (OR 5.73, 95% CI 2.70-12.17; p < 0.0001). Using 
multivariate analysis (controlling for the effects of other variables) respondents were 
ten times more likely to participate in a real trial than a mock trial (OR 9.45, 95% CI 
3.70-24.16; p < 0.0001). This was found to be statistically significant for this study but 
not by Kasner who found no difference in the likelihood of participating in the real and 
mock trials. This may indicate a difference in attitude and opinions in clinical trials 
cross-culturally but may be due to a researcher factor or due to the nature of the 
mock trial itself - being hypothetical. This result was interpreted with caution due to 
small participant numbers for this analysis and the large confidence interval although 
the mock trials were almost identical to their respective real trial counterpart.  
 
Overall, 128 respondents (68%) agreed to participate in a clinical trial of any sort (real 
or hypothetical) despite only a third of patients with known stroke onset time (n=47 of 
141) during the working hours of 9am – 5pm, Monday-Friday. This adds support to 
the case for expansion of the clinical service to become a seven day service with 
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extended hours - which acute research would benefit from being aligned with. A 
potential time delay after admission but prior to research approach was inevitable with 
one researcher and out of hours presentation for many patients. As a result, an early 
contact time-point with consultees was potentially missed. For this study, since the 
acute phase was considered to be 1-7 days (Rocco et al 2007) and commonly within 
the first 72 hours), any impact was perceived to be minimal.  
 
Unwitnessed stroke events accounts for >25% of all strokes (Maas and Singhal 
2013). Terminology in secondary care uses terms such as: ‘last seen well, ‘first 
known unwell’ or ‘wake-up’ stroke to indicate an uncertain event onset time. Clarity of 
onset time can be assisted by advanced imaging (where this is available) but waiting 
for confirmation of diagnosis may delay beyond the time window for recruitment.  
 
5.1.2.1 Study decision-maker 
Stroke patients were able to make the participation decision themselves in 69% of 
cases, higher than in previous studies noted in the literature such as Flaherty et al 
(2008) which reported 30% and Kasner et al (2009) with 47%.  In Kasner’s study, the 
majority of consents were secured within the first 24 hours post event. During this 
early phase, stroke symptoms are often most pronounced and as such, fewer patients 
may be able to consent themselves.  
 
Consultees were used for the remaining respondents in line with current practice and 
following the process for clinical trials where a consultee is approached when patients 
are not able to satisfy the consent process requirements fully.  
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Notably, when presented with a trial participation decision, patients were more 
inclined to agree to participate than consultees were to agree on a patient’s behalf, for 
the patient’s participation. This may be due to patients being more worried about the 
impact of the stroke itself and their wellbeing and therefore being more willing to take 
risks to improve it.  Conversely, consultees may be concerned about the risks of any 
side effects and making the current situation worse with an unproven treatment. 
There is a burden of psychological stress perceived by consultees despite the 
decision-making role being beneficence on behalf of the patient (Rose and Kasner 
2011). In research, a consultee is approached to pass an opinion (as they know the 
patient best), as to whether the patient would be likely to agree or decline to 
participate, should they be able to consent themselves.  
 
Consent sought from a consultee, should represent the patients best interests. 
However, reasoning given for clinical trial participation decision by consultees, 
centred around the consultee’s own perception as opposed to the patient’s likely 
opinion. Consultees often appeared unable to detach themselves from a perceived 
responsibility. There was likely too little time to process all the necessary information 
for a well-considered decision to be made on someone else’s behalf. This is 
highlighted in the results chapter, section 4.1.2 where responses of ‘barely’ and ‘not 
enough’ time for trial consideration were reported and in section 4.3.4 where reasons 
for trial decision are shown (Figures 4.22-4.24). 
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5.1.2.2 Respondent Demographics 
There appeared to be no impact of demographic factors on trial participation, despite 
suggestions of possible influence of age, gender, ethnicity and educational level, in 
previous studies (Corbie-Smith et al 2003; Ding et al 2007 and Glickman et al 2008). 
 
Where stroke patients decided on trial participation for themselves (n= 138, 69%), the 
age of the patient was recorded with a mean age of 66 years. This is younger than 
figures quoted in the three month national stroke audit in 2013 of 77 years (RCP 
2014a) and may be a reflection of stroke incidence, reclassification of TIAs as 
strokes, and advanced imaging (Easton et al 2009). Age remains the single most 
important risk factor for stroke since the risk of a stroke doubles every decade after 
the age of 55 years (Wolf et al 1992). Within the study population older patients may 
have been excluded if unable to consent themselves and had no consultee available 
or fell within the category of too unwell to approach (with probable mortality). These 
patients were not deemed approachable for this study by the clinical care team.  
 
There was variation in age when all ‘respondents’ (including both patients and 
consultees) were analysed with a mean age of the decision-maker of 63.39 years 
since some responders were consultees whose ages varied from that of the patient. 
Some consultees were patient’s children whilst others were a spouse and had a 
closer age to the patient’s.   
 
A large proportion of the study population were from the most socioeconomically 
deprived quartile. The study population achieved representation across the 
socioeconomic groupings and reflected regional and national statistics for the area 
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studied. People from the most socioeconomically deprived areas of the UK, are twice 
as likely to have a stroke than those from the least deprived areas (Public Health 
England 2015), however, no statistical difference was found between socioeconomic 
deprivation scoring and likelihood of trial participation. Whilst socioeconomic status 
(SES) was found to affect early phase cancer trial referrals (Mohd Noor et al 2012), 
once reviewed, deprivation did not affect enrolment.  
 
McLean et al (2006) support the continued existence of the inverse care law (as 
defined by Julian Tudor Hart in 1971 who described the availability of good medical 
care as varying “ inversely with the need for it in the population served” (Hart 1971). 
This may warrant further exploration in terms of research participation since the 
current literature (as regards research) focuses on socioeconomic deprivation linked 
to ill health or responsible for a lack of access to resources including trials (Sateren et 
al 2002, Pell et al 2000). This is opposed to socioeconomic deprivation influencing or 
not, the willingness to participate in trials.  
 
Publicity of research in the community could raise the profile, awareness to and 
understanding of research such that in the event of ill health, a research approach in 
secondary care is not so unexpected or foreign. For example the ‘ok to ask’ campaign 
of recent years by NIHR. Areas of known high risk for particular health conditions are 
likely to benefit from research information, in advance of an ill-health event, if 
communities are within reach.  
 
In multivariate analysis, once the effect of other variables had been controlled for, 
white ethnicity was found to be statistically significant with patients in this group being 
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around three times more likely than non-white respondents to agree to participate in a 
trial (95% CI: 1.03-10.51). This is in contrast to the data on deprivation and maybe 
due to participant factors such as cultural, gender and language barriers if English 
was not a first language or an individual was unable to read English. Trust of medical 
doctor and gender roles in society may also play a part although this was not tested 
within this study.   
 
There is a higher risk of stroke in ethnic minority populations according to the findings 
of Wang et al (2013), Hajat et al (2004) and Scarborough et al (2009). Projections 
from Lievesley (Runnymead report -2010), report the number of older people in the 
UK from ethnic minority backgrounds as increasing as first generation immigrants and 
their families age. Variations in access to healthcare have been highlighted by 
Szczepura (2005) with patients at risk of triple jeopardy (Norman 1985) in the form of 
assumed family support, inequalities in access to healthcare and ill-health - with 
Norman’s early work on older immigrants. Cultural variations may include an 
‘acceptance’ of what has happened and a contentment in being looked after by 
relatives (Salway et al 2007). For others, it may be the expectation of being given 
medication to improve (although this is not unique to patients from ethnic minority 
backgrounds). The research concept therefore that medication, may or may not be 
given and that there is equipoise from a medical perspective may be a barrier for trial 
participation for some minority populations (Scheppers 2006). 
 
Asian elders could experience a loss of status following a stroke and therefore feel 
difficulties with motivation to engage. For another, it was considered to be the “will of 
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Allah” and “any improvements were in the hands of Allah” (Patient, declined study 
and clinical trial outright, with permission given for use of this comment). 
 
Researcher factors in connection with ethnic minority recruitment are not so well 
documented either in the current literature or within this study, although this study did 
achieve representation from ethnic minority groups above regional and national data 
figures.  
 
5.2 Study process 
5.2.1 Communication 
In response to a request to define the term ‘clinical trial’ in the study survey, a large 
proportion of respondents hesitated and struggled to explain the term (see chapter 4, 
section 4.3 regarding the questionnaire response).  Six of 200 respondents (3%) were 
able to correctly define the term ‘clinical trial’ using concepts such as randomization, 
placebo and comparison. Twenty-three (11%) were unable to proffer any answer at 
all. The remaining respondents, all made a fair attempt at the definition with the most 
common answers being “… looking into something”; “testing” and “experiment” being 
mentioned. The definition of a clinical trial from the DH NHS website, was 
subsequently given as part of this study so no misconceptions were held from the 
outset and the survey was then continued to completion.  
 
The implications of 11% of respondents not being able to define the term is a concern 
in the context of gaining valid informed consent for a research trial (Rose and Kasner 
2011). Research consent without understanding may rely more on trust of the 
respondent in the medical professional and absence of coercion (Davies 1997; Wing 
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1999), especially in a time sensitive environment. An explanation of general research 
information, incorporating a definition of the term, could be delivered prior to ill-health 
and be community based – as opposed to extending the consenting process, when a 
trial opportunity presents with the onset of illness. The impact this may have had in 
trials is not clear and a potential area to further explore. 
 
In terms of communication, 52% of participants stated they would have liked to have 
conferred with someone about the trial if they had been available (stating a family 
member in most cases). This was similar to a 57% finding by Kasner et al (2009) in a 
similar study. It was noted on the secondary care wards that visiting was restricted to 
a two hour visit time late in the afternoon plus one hour in the evenings. This was 
reduced further during outbreaks of infectious disease (Norovirus) - when ward areas 
would be effectively ‘closed’, accepting no new ward admissions and stricter visiting. 
This happened on two separate occasions at the first recruiting site, a few weeks 
apart making it difficult to approach relatives to act as consultees if needed or for 
participants to be able to confer with family members. Also, family members did not 
visit every day or due to work commitments, visited in the evening when the 
researcher was unlikely to be present. 
 
The impact that conferring may have had on recruitment is unclear but potentially far-
reaching, beyond recruitment. Within the questionnaire, respondents were asked 
whom they had conferred with, if anyone. In the absence of a family member to 
confer with, participants could have had contact with other medical staff, ward staff or 
other patients in general conversation, which they may have utilised in the decision-
making process either consciously or subconsciously.  
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5.2.2 Cross-cultural comparison 
A comparison was made between this study and findings by Kasner et al (2009) in 
Table 5.1 - both studies recruited 200 respondents using similar survey research 
methodology with a real and mock trial.  A stipulation of the IRB (ethics board for US) 
meant Kasner did not use the NIHSS to score a patient’s stroke severity but asked 
respondents to grade the stroke themselves. Kasner felt this to be a positive since 
their decision should be considered within their own perspective of stroke severity. In 
this study, by comparison, both scorings were recorded: a self-assessed scoring and 
a clinician assessed using the NIHSS.  
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Table 5.1 Comparative data between USA and UK 
Response Kasner et al 
(2009) 
Hyperacute 
This study  
(2013) 
Acute 
Total number of participants 200 200 
Agreed to a clinical trial 57% n=114 64% n=128 
Stroke patient consent for study 47% n=94 69% n=138 
Agreed to a real trial 22% n=44 36% n=72 
Sufficient time to consider trial 56%  85.5% n=171 
Insufficient time to consider trial 38%  9% n=18 
Prior knowledge of consequences       
Positive 
Negative 
Overlap of both 
Total: 
 
30% n=60 
12% n=24 
33% n=66 
75% n=150 
 
30.5% n=61 
18%    n=36 
12.5% n=25 
61%    n=121 
General attitude 
Very positive 
Positive 
Neutral 
Negative 
Very Negative 
 
5%  
45% 
44%  
5%  
2%  
 
8.5% 
57.5% 
26% 
8% 
Decision made solely by respondent 72% n=144 60% n=120 
Sole decision-makers who would have liked to have 
conferred with someone 
57% n= 82 43% n=52 
 
From Kasner’s study, American respondents had been more aware of consequences 
of research generally, prior to the research contact - with over double having heard 
something both positive and negative about research previously, in comparison to UK 
respondents. 
 
Kasner used a ‘hyperacute’ stroke research trial and mock, whereas in comparison, 
an ‘acute’ phase stroke research trial and mock was used in this study due to the 
service advancements in hyperacute still being under development in large parts of 
the UK. From this respect, caution needs to be applied with a direct comparison of 
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data with Kasner. The hyperacute phase of a stroke although only recently separated 
from the acute phase and only a matter of hours earlier, could hold sufficient 
difference to make any comparison speculative.  
 
More UK respondents agreed to participate in an acute stroke trial than their 
American counterparts, in a hyperacute stroke trial. It is not clear whether British 
respondents were more likely to participate in trials but they reported a positive 
attitude towards trials, having heard less about trials overall. By comparison, 
American respondents appeared more cautious with fewer agreeing to participate and 
a larger number of respondents having heard about research previously. 
 
More respondents in Kasner’s sample in the hyperacute phase felt they had 
insufficient time to make a decision, compared to this study, conducted in the acute 
phase (38% vs 9%), Reflecting possible differences in the phases of stroke. Urgency 
is fundamental in acute stroke research trials, however, respondents should not feel 
hurried. Sen Biswas et al (2007) suggested support for research from medical staff 
and family may improve recruitment. More research contact points may prove 
beneficial especially if the concept of research is new to potential participants, either 
by telephone or in person and the role of pre-hospital staff raising the possibility early 
and discussion en-route to the emergency department have a potential to increase 
recruitment (Leira et al 2009). 
 
In common with Kasner et al, this study found consultees less likely to agree to 
participation, than patients themselves. Highlighting this to consultees who may have 
felt the burden of responsibility in decision-making, might reassure and ease the 
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decision-making process. Exploring a patient’s affinity, perceptions and attitudes to 
guide the research opportunity presented might also reassure consultees that the trial 
is tailored to the individual e.g. they have high blood pressure and the trial being 
offered is to manage high blood pressure.  
 
Kasner et al (2009) found no association with participants self-graded level of stroke 
severity. However, in this study those participants with more severe strokes were 
statistically more likely to participate in a research study (as noted in chapter 4, 
section 4.2.4). In relation to the stroke itself, disparity was found between clinician 
assessments of stroke severity using NIHSS versus respondent self-assessed stroke 
severity. Self-assessed stroke severity was determined on an individual level, by the 
individual themselves.  Any attempts of explanation to account for this difference in 
rating would be purely speculative and it was not the aim of this study to explore 
disparity between participants and clinician’s assessments of stroke severity.  
 
Assessment of stroke severity did coincide with a reported points-drop on a health 
scale from previous wellness, which was captured on the study questionnaire. Self-
assessed stroke severity was a statistically significant finding. Patients who assessed 
their own level of stroke severity as moderate or severe were significantly more likely 
to agree to participate in a trial than those who considered their stroke to be mild (X2 
= 9.87, p=0.031). Using Chi-square for trend, the likelihood of agreeing to participate 
in a trial was increased as perceived stroke severity increased (X2 = 4.674, p=0.031).  
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5.3 Potential Influences on participation  
Not knowing a patient’s affinity, perceptions and attitudes to research, medical staff 
consider the eligibility criteria for a research opportunity for patients as opposed to 
what trial the patient might be most interested in. Personal affinity may play a part in 
decision-making and retention in research trial. For instance, high blood pressure was 
a common risk factors reported by respondents and the proportion that agreed to take 
part in a trial was higher than any other risk factor (although not statistically 
significant). The mock trial was a drug trial related to blood pressure and several 
respondents commented that there was something about the trial that they liked as an 
influence in their participation decision and a ‘blood pressure trial’ was named 
positively on three occasions in regard to participation. 
 
Where multiple or competing trials are open at a site, medical bias for one trial being 
offered over another may conceivably exist with factors such as the 70 day national 
NIHR target to meet; a financial incentive from pharmaceutical industry sponsored 
study or a home-grown site-sponsored study being a recruitment pressure.  As a 
result, a trial opportunity may therefore be presented in a skewed fashion as opposed 
to consideration from the patient perspective of what they would be keen to 
participate in, limiting patient’s choice. Trials are often opened due to a personal 
interest from medical teams. Local populations whilst considered for recruitment 
target numbers are not necessarily canvassed for what they want to be available in 
research in the local or regional secondary care Trust. 
 
Once a patient has declined to take part in research, the reason for that decision is 
not always noted in the patient records. A second research opportunity may not be 
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presented due to the limited resource of researchers or trial time restrictions leading 
to failed screening no longer meeting eligibility. Also, patients may then have a 
preconditioned response to what they understand to be research, which may be 
misinformed. Researchers conversely may assume patients to have already made up 
their mind against research and be hesitant to reapproach a patient when in fact the 
previous decision was trial specific. Three respondents agreed to a trial when they 
had declined a different one initially. 
 
Giving a choice of trials may not be appropriate and could complicate a decision on 
participation. The added choice of deciding between trials could be too much to ask of 
the acutely unwell, neurologically affected patients and their close relatives. Whilst not 
within the remit and scope of this study, future work could inform practice. 
 
5.3.1. Motivators 
Motivators and barriers to clinical trial recruitment are documented in the literature 
(Prescott et al 1999, McDonald et al 2006 and Treweek et al 2011). Within the current 
literature perceived personal benefit (to help self, better care and access to the latest 
treatments) and altruism are frequently cited motivators for participation in prevention 
and chronic disease trials (Corbie-Smith et al 2003; Cassileth et al 1982). Also 
mentioned is doctor’s recommendation, hope for a therapeutic benefit, only option 
and curiosity (NIH 2002).  Although motivators have been less frequently researched 
than obstacles and barriers. Cross-culturally motivators may vary for instance in USA, 
literature cites free drugs (NIH 2002) as motivational factors for participation and by 
comparison, healthcare regimes in the UK are different with excess treatment costs 
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for drugs being covered traditionally by the NHS (particularly cancer studies until 
recently).  
 
The content of the trial offered might have contributed towards motivation to 
participate. Blood pressure is a contributing factor to over half of all the strokes in the 
UK (RCP 2014a). This was also the commonest risk factor for respondents in this 
study and a high proportion of respondents with high blood pressure agreed to 
participate in a trial. A real trial offered at one recruiting site was a blood pressure 
study and the mock trial was a blood pressure trial at both sites. Due to small 
numbers, it was not possible to ascertain significance between an individual’s blood 
pressure status and trial participation at a statistical level. 
 
The most common motivating factors from the thematic analysis in this study were 
cited to be altruism and ambivalence.  
 
5.3.2 Barriers 
Barriers lead to trials either failing to meet targets and thus their objectives, with 
financial and resource waste. Limited resources may be diverted for trial extensions 
to meet recruitment targets and therefore distract or limit the support for new trial 
work. Barriers to recruitment have been a focus in clinical research, historically 
documenting issues surrounding consent (in the ethics literature) and more recently 
focusing on recruitment as targets are analysed at a national level.  
 
Potential negative external influences include: rigid entry criteria; perception of costs 
in both time or monetary value and no suitable trial.  Fear and mistrust are equally 
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cited in the literature with limited attention given to benefit / burden balance for 
participant. Within this study, personal fears of being a “guinea pig”, of side effects 
and of the unknown were cited for refusal (see chapter 4 results, section 4.3.4 on the 
participation decision, Figures 4.22-4.24) supporting previous work by Corbie–Smith 
et al 2003 and Madsen et al 1999 which also found feeling overwhelmed, perceived 
risk outweighed perceived benefit or participants had a preference for outcome (of 
randomisation). 
 
Whilst participant barriers have been noted in the previous literature, less well noted 
are clinician barriers to recruitment. These can include time due to the pressures of 
normal clinical practice and the time demands of recruitment and follow-up; perceived 
importance of the trial; the doctor-patient relationship- in particular clinicians’ 
declaring equipoise and Incompatibility of the trial protocol with normal clinical care. 
The reasons for recruitment failure are rarely documented in medical records and 
thus add an uncertainty to identifying barriers and putting strategies in place to 
facilitate and ultimately increase recruitment. The most common barriers from the 
thematic analysis in this study, was cited to be: something trial related, disinterest in 
the trial topic and feeling overwhelmed.   
 
Additional points of contact for research may assist in addressing patients and 
consultees feeling overwhelmed at the prospect of research participation. Raising 
awareness about research in the community may help reduce disinterest and 
increasing the choice of trials available and tailoring a choice to a patient’s affinity, 
may assist in addressing trial related negatives.  
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Further work may also be needed on the information exchanged by medical 
personnel in regard to stroke to enable patients and their families to give fully 
informed consent. For example patients were more likely to say yes when asked 
themselves (Section 4.1.2; Figures 4.4-4.5). Also more respondents rated the stroke 
as severe, than the clinician scoring rated them (section 4.2.4; Figures 4.8-4.9) and 
more people want to take part in trials if they perceive themselves as severely 
affected. These findings, if conveyed to potential respondents of future trials may 
alleviate some burden of responsibility for consultees and reassure both consultees 
and patients. 
 
5.4 Strengths and limitations of this study 
Survey research methodology – the chosen methodology for this study, is open to 
critique in the literature due to data that may lack detail or depth. Also, one particular 
research technique in isolation may not be ideal to allow for multicultural variations of 
participants and strategies for improved recruitment maybe required (Hussain-
Gambles et al (2004). 
 
Not all stroke admissions were captured by the research approach used in this study, 
largely due to only one researcher being available (section 4.1.1; Figures 4.2-4.3 and 
section 5.1.2). Potential respondents, ‘eligible but missed’ from a research approach 
were lost to research. A limitation of the data is recognised in that it captures only 
those approached and consented. 
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A questionnaire developed for US patients may not be applicable to the UK 
population. A PPI group reviewed the trial paperwork; the questionnaire was piloted 
and was subsequently adapted for use in the UK.  It may, however, not have allowed 
for all potentially influencing organisational factors, particularly if these were not 
apparent.  
 
Cross-continental and different ethnic cultures may affect direct comparison of the 
data. Whilst the mock trial was fully integrated in clinical care, the real trial was 
delivered without the study researcher necessarily being available. As such, the study 
details were completed in retrospect for some respondents.  Any time delay was 
minimised, where possible, as it was recognised that recall of details may be poor for 
some respondents, particularly over time. 
 
Thematic analysis is inherently interpretive research open to biases, values and 
judgements of researchers (Creswell 1994). The limitations of the analysis were 
recognised. Whilst the qualitative element of the study was a small thematic analysis, 
in terms of recruitment a physical aspect to the findings was for new knowledge and 
better care with self-actualisation, to help self and others in the future. 
 
5.4.1 Strengths 
In terms of strengths, the study design was prospective. Respondents were able to 
verbalise a reason supporting the participation decision and did so prior to any 
prompt.  
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Prompt responses were interpreted with caution since they may not have had a role 
in decision-making but sounded plausible when considered subsequently. Responses 
to prompts largely supported the reasoning verbalised by respondents for trial 
outcome decision adding credence to the initial rationale.  
 
With one researcher, there was consistency in approach, explanation and delivery of 
the survey, minimising influencing factors which may otherwise have arisen. One 
researcher would not necessarily have improved trial agreement but did provide 
consistency across the 200 respondents. This was at the expense of lack of available 
researcher at times.  
 
5.4.2 Limitations 
A proportion of the stroke admissions at each recruiting site were ‘lost to research’ 
beyond those originally predicted, due to limited researcher time – although 
recruitment numbers were met within the time frame of the study. Respondents were 
not always approached at the earliest possible opportunity, often due to clinical care 
requirements or a delay due to the need for a consultee to be present. The variation 
in timings of the research approach may have introduced bias but reflected the usual 
process for trial recruitment, on sites, for acute trials. Also at times, there was limited 
researcher availability. This was a result of not achieving NIHR recognition, an e 
accreditation which would have enabled access to NIHR resources (research staff) 
and in the absence of alternative financial support over and above the studentship.  
 
The study population was too small for a robust analysis of the effect of ‘timing of 
research approach’ to be undertaken. Kasner et al (2009) achieved a higher 
 126 
proportion of approaches in the first 24 hours but fewer respondents agreed (although 
a high proportion (85%) felt happy with the time given to consider the opportunity). 
Symptoms can vary a lot in the first 24-48 hours of a stroke and this might explain 
variations in personal perception of stroke severity to an extent and the decision 
taken in light of the complications of stroke. 
 
This study approach was not as integrated for the real trial consideration as the mock  
- the latter of which was integral to the initial research approach. A slight time delay 
was noted between the real trial and completion of the survey although this was 
recognised from the outset of the study and minimised as much as possible. This was 
in contrast to Kasner et al (2009) who used the initial study approach prior to any 
clinical trial presentation (real or mock).   
 
Real trial opportunities were offered with and without the presence of this study’s 
researcher. It is recognised that more decliners could have been captured by this 
study if more personnel had been available – Kasner reporting that he used a team of 
researchers whilst this study used only the author. 
 
It was not always documented in the medical records when a patient declined a real 
trial approach. Recording of the rationale behind this decline could have provided 
informative data. This study would also have benefited from exact alignment with 
clinical research opportunities offered and more real trials being open at recruiting 
sites (trial offered being statistically significant in terms of participation).  At the outset 
of this study, nine real trials were open at recruiting sites. This dropped to 3-4 
 127 
following commencement of the study and lead to reduced research participation 
opportunities for patients.  
 
Several timings of initial study approach were noted (section 4.2.5). It is possible that 
the same participants approached at certain times during stroke admission may have 
had a different response (section 4.5.2.1). 
 
Limited thematic analysis was undertaken but should be recognised for its limitations. 
Comments cited during the thematic analysis as verbalised by consultees, reflected 
an inseparable influence of personal perception. It is highly possible that responses 
may have been time sensitive with influence of how the patient was clinically, felt or 
looked, if they were sleeping or showing any change in condition. An example of 
comments given include the following: 
 
“…it could help him or someone else, monitored all the time”. (Consultee, aged 49 
years, agreed for patient to take part).  
“…don't really want to put her through anything else because of what she's been 
through already”. (Consultee, aged 79 years, declined for patient to participate). 
“…reluctant as not clear diagnosis but agreed because of blood pressure. Important 
to do these things, if got something yourself, doing a trial in that would help others in 
the future.” (Patient, aged 42 years, agreed to take part). 
 
Consultees were those available at visiting hours, which were restricted in the number 
of visitors allowed and timing of visiting hours. It was possible that it was not 
necessarily the most suitable family member who was approached although this was 
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verbally checked on initiating the approach. Family disputes, argument and lack of 
agreement between different consultees were noted to some extent for a small 
number of respondents. On a particular day, less close relatives or non-family 
members might have been visiting and it is possible that the consultee approached 
did not necessarily feel best placed to make a research decision. Attempts were 
made to establish this at the outset of each approach and the consultee’s relationship 
to the patient (if used as decision-maker) was noted on the questionnaire. This relied 
upon limited information and the confidence of the consultee to act on their relative’s 
behalf. Having no close family also challenged recruitment.  
 
5.5 Summary 
The aim of this study was to answer the research question of what influences 
decision making for clinical trial participation in the context of acute stroke and 
whether there are any identifiable factors indicative of participation.  
 
This chapter has aimed to discuss the characteristics of recruiting sites and of 
respondents to clinical trials in the acute stroke phase. Demographic factors, level of 
education, prior research experience and issues related to the stroke experience itself 
have been explored. There is no suggestion of any impact on the decision to 
participate in acute stroke trials with the exception of self-assessed stroke severity.  
 
Decision-making by potential participants in stroke trials is complicated by an 
unexpected decision needed in a short time frame requiring information to be read, 
understood and acted upon in someone else’s best interest with unclear diagnosis 
and uncertain prognosis in an acute secondary care environment with a genuine rate 
 129 
of stroke mortality or permanent disability. As such, stroke presents unique research 
challenges (Carman et al 2014). 
 
General attitudes towards clinical trials were found to be largely positive with little 
recognition or weighting placed on external factors (whether this is due to a lack of 
awareness to any influence, denial or subtlety is still unclear). Differences were found 
in the rationale behind patients and consultees decision-making.  Participation for 
both groups was most likely with a real trial as opposed to a hypothetical (mock) trial.  
 
Having reflected on these points, it is possible to acknowledge the achievements of 
this study and also recognise areas for future work. These conclusions are presented 
in the final chapter.  
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CHAPTER 6 
CONCLUSION 
 
 
This study set out to determine the factors associated with stroke patients’ 
willingness to participate in acute stroke trials. Influences, attitudes and perceptions 
regarding participation were explored, alongside health status and demographics. 
The study has successfully documented prospective findings from 200 respondents 
completing a survey and considering a clinical trial, during admission for an acute 
stroke. In this chapter, the key findings of this study will be reviewed and areas of 
further work will be highlighted with implications for CRN policy. 
 
Recruitment to clinical trials continues to be a focus in the UK but this study is one of 
only a small number to emerge in recent times within stroke care. Whilst those 
choosing to decline a study are often lost to research and the rationale unrecorded, 
potential participants were successfully engaged and a verbatim response recorded.   
 
Findings reveal that sociodemographic factors such as age, gender or ethnicity did 
not explain decision-making about clinical trial participation in acute stroke research, 
in its entirety. Decisions about participation in trial research are more likely to be 
strongly influenced by a potential participant’s attitudes, perceptions and prior 
knowledge or experience of clinical trials. Therefore, more could be done to recruit to 
trials centred around the individual potential participant.  
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This study found that agreement to participate was more likely in a real trial than a 
mock (hypothetical) trial in the context of an acute stroke. Views expressed by 
respondents regarding the rationale for their participation decision suggest that trials 
with a focus on a particular clinical condition or co-morbidity such as blood pressure, 
or those focused on a particular patient cohort (e.g. a specific ethnic group) were 
more likely to be perceived favourably by stroke patients or their consultees. 
 
Patients who were able to consent for themselves were more likely to agree to trial 
participation than consultees considering trial participation on behalf of a patient who 
was unable to consent. Some consultees reported a ‘burden of responsibility’ in 
decision making for an acute stroke clinical trial. Presenting a trial for consideration 
by reviewing not only eligibility but also knowledge of the patient as to whether this 
would be a trial they would feel an affinity towards, may improve recruitment rates 
further and reassure consultees of an individualised plan of care. This could provide 
reassurance and ease any decision burden by informing of a more individualised 
recruitment strategy. 
 
There are challenges associated with presenting individuals with a choice of trial 
within which to participate (to maximise recruitment), weighed against the choice 
being perceived as an added burden -to the detriment of potential participants who 
may decline due to feeling overwhelmed. 
 
In this study, a personal perception of the stroke being severe (by the respondent) 
was more likely to result in trial participation. It is not evident how a patient or 
consultee deduces severity and there was disparity in personal perception and 
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clinician scoring on a severity assessment tool (NIHSS). More respondents 
considered themselves as severely affected than clinicians did. Where alternative 
consent is sought for trial participation, this disparity could be highlighted as it may 
lessen the perceived ‘burden of responsibility’ yet further.  
 
The terminology in research is not always clearly understood by participants and 
misconceptions may exist with an inability to define the term clinical trial at the outset 
of the research opportunity. Potential participants may benefit from additional 
research contacts and increased community awareness to understand a definition 
prior to a hospital admission. 
 
The rationale behind trial participation decisions is not easily elicited but due to 
challenges of recall in the acute setting, in the context of stroke, would be best 
placed immediately alongside a research opportunity. Recall after an acute 
neurological event would be best placed as fully integrated within real trials 
opportunities at the earliest opportunity. If questioned at a later date, the trial may not 
be easily recalled suggesting informed consent may not be truly informed (Rose and 
Kasner 2011) and remembering the rationale behind a trial decision maybe even 
more vague.  
 
 
6.1 Recommendations for future work 
A question as to what influences perceptions of event severity with acute stroke 
remains and warrants further work due to a disparity in the perception by those 
affected and in that measured by health care professionals using a validated clinical 
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assessment tool (NIHSS). In addition, the participation of ethnic minority groups 
needs continued exploration and potential participants across all groups may benefit 
from additional research contact points during admission. White ethnicity was found 
to increase the likelihood of trial participation. Whilst the respondents for this study 
were ethnically diverse and non-white patients responded to the survey in greater 
numbers than the regional and national average, the likelihood of agreement to take 
part in a clinical trial within the survey was statistically lower in the non-white ethnic 
group. The explanation behind this is still not clear and would benefit from future 
work.  
 
Trials embedded within an overarching programme which tests recruitment strategies 
prospectively - whilst recruiting to a ‘live’ study could improve recruitment strategies 
and design approaches for disease, cohort or institutional specifics (MRC START 
2012). Future work would also benefit from focusing not only on the reasons that 
patients agree or decline trial participation, but understanding the reasons why 
clinicians may not focus resources on enhancing trial recruitment. 
 
Many actively recruiting research studies on the NIHR portfolio and other commercial 
studies currently have an international reach. International collaboration is 
recommended as a result of this study to enable larger sample size analysis and 
cross-cultural comparison for variance in order for global studies to increase 
recruitment efficiency.  
 
Similarities with Kasner et al (2009) - who used similar methodology - include the fact 
that approximately half of respondents in both studies would have liked to have 
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conferred with someone prior to decision-making. This did not prevent a decision 
being made but the decision itself may have been open to influence (positive or 
negative) if another person had been available. Having heard only positive or 
negative consequences of research previously had similar numbers across both 
studies, however, those respondents having heard both positive and negative reports 
previously, were potentially more research aware and those respondents in the US 
sample were double the number compared to the UK.  
 
Differences were noticeable in those agreeing to participate in a clinical trial with 
statistical significance in the UK but not the US for self assessed stroke severity and 
whether the trial was real or mock. A different ethnic group was studied in the UK and 
found significance in the likelihood of those of white British as opposed to other 
ethnicities, in agreeing to participate in a trial.  However, because of sample sizes 
some sub-analysis was not possible but could be enabled in the future with 
collaboration and potential meta-analysis of similar studies. 
 
6.2 Recommendations for future policy 
As Britain continues to move towards further ethnic diversity and with the increase in 
the number of internationally recruiting trials, representation requires a concerted 
effort. The emphasis applied by the NIH in the US in 1990s to this end has not been 
replicated in the UK to date and maybe necessary to make sufficient strides towards 
inclusive representation (Redwood and Gill 2013).  
 
Recruitment continues to be a focus and representative, timely recruitment is 
fundamental for trial success. The CRN has produced guidance, which emphasises 
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efficiency and timely processes. Whilst this is necessary for maximising potential 
research opportunities, Trusts must also be aware of potential financial implications 
from the NIHR when self-setting targets, with an expectation of 100% achievement. 
National league tables rank Trusts in terms of meeting a 70 day recruitment target 
and consequently Trusts would do well to work with recruitment strategies to a 
greater extent.  
 
Much of the research training available locally is provided by the CRN. Perception of 
stroke severity has implications for communicating in clinical trials and the training 
requirements to successfully recruit to time and target (high level objectives of the 
CRN). Whilst consent training is available, due to the crucial role of recruitment, 
much could be gained from teaching recruitment strategies to generic researchers. 
 
Previously, research on barriers to recruitment has been speculated on by members 
of the general public as opposed to prospective on actual patients who have declined 
a clinical trial or were ineligible. This study has enabled non-responders and 
decliners to be analysed prospectively, alongside those agreeing to participate in a 
clinical trial, filing a knowledge gap of why some UK acute stroke patients are willing 
to participate in acute stroke trials and why others decline or it is declined on their 
behalf. This study has achieved its objectives in studying the willingness to 
participate in acute stroke research trials, but its impact on future trial design has yet 
to be realised. 
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